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	ABSTRACT  
 
This thesis reports an integrated analytical approach for the study of physicochemical 
and biological properties of new synthetic bile acid (BA) analogues agonists of FXR 
and TGR5 receptors. Structure-activity data were compared with those previous 
obtained using the same experimental protocols on a large series of synthetic and 
natural occurring BA.  
The new synthetic BA analogues are classified in different groups according also to 
their potency as a FXR and TGR5 agonists: unconjugated and steroid modified BA and 
side chain modified BA including taurine or glycine conjugates and pseudo-conjugates 
(sulphonate and sulphate analogues). 
In order to investigate the relationship between structure and activity the synthetic 
analogues where admitted to a physicochemical characterization and to a preliminary 
screening for their pharmacokinetic and metabolism using a bile fistula rat model. 
Sensitive and accurate analytical methods have been developed for the quali-
quantitative analysis of BA in biological fluids and sample used for physicochemical 
studies.  
Combined High Performance Liquid Chromatography – Electrospray – tandem mass 
spectrometry (HPLC-ESI-MS/MS) with efficient chromatographic separation of all 
studied BA and their metabolites have been optimized and validated. Analytical 
strategies for the identification of the BA and their minor metabolites have been 
developed. Taurine and glycine conjugates were identified in MS/MS by monitoring the 
specific ion transitions in multiple reaction monitoring (MRM) mode while all other 
metabolites (sulphate, glucuronic acid, dehydroxylated, decarboxylated or oxo) were 
monitored in a selected-ion reaction (SIR) mode with a negative ESI interface by the 
following ions. 
Accurate and precise data where achieved regarding the main physicochemical 
properties including solubility, detergency, lipophilicity and albumin binding . These 
studies have shown that minor structural modification greatly affect the 
pharmacokinetics and metabolism of the new analogues in respect to the natural BA and 
on turn their site of action, particularly where their receptor are located in the 
enterohepatic circulation. 
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1. INTRODUCTION 
 
1.1. PHYSIOLOGY OF BILE ACIDS 
 
1.1.1. The structure of natural bile acids 
 
In vertebrates, cholesterol, a major lipid constituent of all biological membranes, is 
converted into amphipathic derivatives soluble in water that are secreted into the bile. 
As a family, these molecules are called bile acids (BA) or cholanoids. Unconjugated BA 
once synthesized are mainly conjugated BA with taurine and glycine, but also sulphates 
and other conjugates of bile alcohols, as well as glucuronides and N-
acetylglucosamidates.  
The first mechanism of BA biosynthesis is de novo synthesis from cholesterol in the 
epathocyte (primary BA); the second is the modification of the hydroxyl substituents by 
of the enzymes of the intestinal bacterial flora, with formation of secondary BA. Figure 
1.1 shows a schematic representation of BA biosynthesis pathways. In the classic 
pathway, cholic acid and chenodeoxycholic acid, two primary BA in humans, are 
formed. In the alternative pathway, mainly chenodeoxycholic acid is formed.  
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Figure 1.1: Schematic representation of BA biosynthesis pathways. 
 
The BA molecule can be considered as consisting of two parts: the steroidal ring and the 
side chain. 
 
 Side Chain: The structure of the side chain determines the main BA classes . The 
side chain of cholesterol contains eight carbon atoms, with ramifications in C20 and C25; 
if the terminal carbon (C27) is hydroxylated, bile C27 alcohols are formed, if oxidized to 
carboxyl, BA C27 are formed (cholestanoic acids). If the side chain undergoes oxidative 
carboxylation with formation of a chain C5, the result is BA C24 (cholanoic acids). 
There are also naturally occurring bile alcohols C26, C25 and C24. 
In many mammals and in most vertebrates, BA C27 or C24 predominate (Haslewood et 
al. 1978). Bile alcohols, such as sulphates, are present in appreciable quantities only in 
the most primitive species (elephant, hyrax, rhinoceros, walrus) (Hagey et al. 1992). In 
birds, BA C27 and C24 predominate, while bile alcohols (sulphate) are present in 
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primitive fish (e.g. sharks) and reptiles and may be the main constituent of bile. 
Alligators, crocodiles and turtles produce mainly BA C27 (Hagey et al. 1992). The 
presence of a hydroxyl in position C23 or C22 is also possible; in the first case we speak 
of α-hydroxy BA (some marine mammals), in the second of β-hydroxy BA (some fish). 
 
 
Figure 1.2: Differences between cholesterol and BA C24 
 
 Steroidal ring: In higher vertebrates, the rings A and B have the cis 
configuration, giving a bent structure to the nucleus; since the hydrogen in position 5 is 
in the configuration β, these compounds are called 5 β-BA. In lower vertebrates, some 
BA and alcohols are flat because of the trans junction of rings A and B (Hagey et al. 
1992, 1995); the 5 α-BA are also called Allo-BA. In some genetic diseases of the 
metabolism of BA and conditions of cholestasis, BA whose nucleus still contains Δ5,6 
(the double bond between the carbons 5 and 6), typical of cholesterol, can be 
synthesized. The pattern of substitutions in the ring of the hydroxylic BA (and alcohols) 
derives from site-specific hydroxylations. Since cholesterol has a hydroxyl in C3, all 
natural BA must have a hydroxyl C3. Also, since the 7 α-hydroxylation of cholesterol is 
the limiting step in the biosynthesis of the speed of BA in all vertebrates (Russell et al. 
1992), all the BA must have a primary hydroxyl C7. The 3α,7α-dihydroxy-5 β-cholan-
24-oic acid (chenodeoxycholic acid, CDCA) can thus be considered the starting point 
for all “modern” (C24) BA. In many vertebrates, there is a further step of hydroxylation 
in the ring, with the result that the most important BA formats in the liver are CDCA 
(3α, 7α-dihydroxy) and CA (3α,7α,12α-trihydroxy-5β-cholan-24-oic acid). In non-
mammals, there are other possible positions: 3,7,16-trihydroxy BA are extremely 
common in birds (Hagey et al. 1992) and 1,3,7 trihydroxy BA have recently been 
 Cholesterol BA 
Sterol C27 C24 
Side chain C8 C5 
Double bond Δ5 - 
Hydroxylation - C-7 
A/B ring - Hβ (cis) 
C-3-OH β α 
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identified as the main BA of some vertebrates (Hagey et al. 1994). The BA in which the 
hydroxyl is in configuration rather than in α (or α instead of β) are defined as epimers. 
In rats and mice there are significant quantities of 3α,6β,7α- and 3α,6β,7β-trihydroxy 
AB, called muricholic acids, synthesized in the hepatocyte for 6β-hydroxylation and 
possible epimerization of hydroxyl 7α (Waxman et al. 1991). 
 
1.1.2. Hepatic metabolism of bile acids 
 
In the hepatocyte, both the neo synthesized BA and those captured by the blood can 
undergo a series of biotransformation, in particular conjugations with glycine and 
taurine, and to a much less extent esterifications with glucuronides, sulphates, glucose 
and N-acetylglucosamine. The glucuronidation can take place in the hydroxyls on the 
side chain or the nucleus (ethers glucuronides) or on the carboxyl side chain (ester 
glucuronide). The esterification with sulphates, glucose and N-acetylglucosamine, 
instead, takes place only on the hydroxyls.  
The amidation occurs in two steps: a first cytosol enzyme (coenzyme A ligase) 
reversibly transforms the BA into its CoA derivative (Killenberg et al. 1978; Vessey et 
al. 1977), which is irreversibly converted by a second microsomal enzyme (colil-CoA 
transferase amino acid) to BA tauro or glyco conjugate (Czuba et al. 1986; Vessey et al. 
1979 ), which is then secreted into the bile. The rate of conjugation is strongly 
influenced by the structure of the side chain of the BA; C23 nor-BA in fact do not form 
amidated derivatives (Czuba et al. 1982). The second enzyme preferentially uses taurine 
rather than glycine. Taurine in humans is synthesized only in limited quantities, and 
consequently the main source of taurine available for the conjugation of BA is the diet 
and consequently the main amidation is with glycine.. Even conjugations with 
glucuronides (Takikawa et al. 1985), glucose (Matern et al. 1987) and N-
acetylglucosamine (Marschall et al. 1989) are minor metabolic pathways for natural BA 
in healthy humans, except in the case of the hyodeoxycholic acid, massively 
glucuronidated in position 6 (Radominska-Pyrek et al. 1987). 
The BA amidated are actively absorbed by the intestine even if highly hydrophilic while 
the conjugation with glucuronide and sulfate leads to a rapid elimination of the BA with 
stool or urine. 
	 8
1.1.3. Intestinal metabolism of bile acids 
 
When the BA reaches the intestinal regions rich in bacteria, they undergo a series of 
biotransformations (Mac Donald et al. 1983). In humans, the bacterial flora begins to 
increase in number and diversity in the terminal ileum, with a marked increase in the 
cecum. The changes that occur in the ileum of BA are due to aerobic or facultative 
anaerobic, while in the cecum are probably due to strictly anaerobic bacteria. 
The main biotransformation i.e. their side-chain deconjugation is catalyzed by a large 
number of bacteria (Bacteroides, Clostridium, Lactobacillus, Bifidobacterium, 
Eubacterium and Escherichia); the enzyme involved is called cholyglycine hydrolase 
and that isolated from Clostridium perfringens has been characterized in detail with 
regard to its activity against structurally different BA  
The second major metabolic pathway is the oxidation, of the hydroxyl groups in 
positions 3 , 7 and 12 to form oxo derivatives by different bacterial dehydrogenases  
The most relevant biotransformation, due to anaerobic bacteria in the cecum, is the 7-
dehydroxylation of primary BA, CA and CDCA, with the formation of respectively, 
deoxycholic acid (DCA) and lithocholic acid (LCA), the two major secondary BA in the 
human bile. The amount of 7-dehydroxylation varies considerably between different 
species of animals; in rabbits the 7-dehydroxylation of CA is so massive that DCA is up 
to 95% of the pool of BA.. Generally the enzyme is less active against BA 7β-
hydroxylated (White et al. 1982) and does not act on BA glycine/taurine conjugates 
(Batta et al. 1990). 
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Figure 1.3: Structure of the major BA in man. 
 
 
1.1.4. Enterohepatic circulation of bile acids 
 
The distribution of BA is essentially limited to the liver, bile ducts, intestines and 
circulatory system. The enterohepatic circulation of BA is a dynamic entity in which the 
BA "pool" (i.e. their mass) recirculates constantly but mainly after meals, carrying out 
its physiological functions and undergoing the processes of synthesis as well as hepatic 
and intestinal biotransformations (Hofmann et al. 1989; Vlahcevich et al. 1990). A 
representation schematic is shown in the Figure 1.4 below.  
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Figure 1.4: Schematic of the enterohepatic circulation 
 
The total pool of BA is 4-6 gr; this remarkable mass recirculates in the enterohepatic 
circulation (EHC) at least 5-9 times a day, depending on the contraction of the 
gallbladder and intestinal motility. 
The EHC of BA is made possible by the existence in the enterocytes two mechanisms 
passive and active of BA absorption and transport : passive absorption can occur along 
the entire intestinal tract and depends on the pH of the intestine and the pKa and the 
lipophilicity of the BA (Dietschy et al. 1968; Angelin et al. 1976; Schiff et al. 1972). A 
greater lipophilicity increases the probability that the molecule will cross the cell 
membrane (Cabral et al. 1987). The absorption is much greater for non-ionized 
molecules compared to ionized ones; since the pKa of the free BA, and tauro and glyco 
conjugates is respectively about 5, 3.9 and 1, and the pH of the jejunum, ileum and 
colon approximately 6, 8 and less than 7, only in the jejunum and colon will the BA be 
protonated in appreciable amounts free and to a lesser extent the glyco conjugates. In 
reality, only the colon is important in the absorption of passive free BA, as in all natural 
BA physiological conditions in the fasting conjugates. 
The active absorption of BA occurs in the distal ileum and is due to a transport system 
coupled to the sodium localized in the apical membrane of ileocyte (Lin et al. 1988 ; Lin 
et al. 1993). This active transport takes place according to the kinetics typical Michaelis 
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Menten, described by a maximum speed of transport (Vmax) and a rate constant (Km), 
Only taurine and glycine conjugated BA are absorbed thanks to this active transport 
system. 
 
 Hepatic uptake: The BA reach the liver by the intestine via portal vein. The BA 
are present in the serum bound to albumin, a proportion that varies from approximately 
80% for the less hydrophobic compounds (e.g. TCA) to 95-99% for the mono and 
dehydroxylated free and conjugated BA (Roda et al. 1982). A small fraction of the BA 
(<10%) is bound to lipoproteins (Hedenborg et al. 1988). Uptake is due to two transport 
systems, a sodium dependent system and a sodium-independent system (Von Dyppe et 
al. 1983; Ananthanarayanan et al. 1988; Hagenbuch et al. 1991; Aldini et al. 1982, 
1986).  
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1.2.BILE ACIDS A ANALOGUE SIGNALING PATHWAYS AS 
THERAPEUTIC TARGETS  
 
BA are signaling molecules that exert genomic and non-genomic effects by activating 
the farnesoid X receptor (FXR, Figure 1.5), a member of the nuclear hormone receptor 
superfamily and also TGR5 (M-BAR, GP-BAR1 or BG37) a G-protein-coupled 
receptor. It has been previously found that some BA analogues act only on FXR 
receptors but others are specific for both FXR and TGR5, opening unexpected 
therapeutic opportunities not only for the treatment of cholestatic liver diseases like in 
primary biliary cirrhosis (PBC) but also in metabolic disorders of lipid and glucose 
homeostasis including diabetes and the metabolic syndrome (Fiorucci et al. 2009). 
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Figure 1.5:. FXR- and TGR5-mediated regulation of BA 
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1.2.1. FXRα agonists  
 
FXR was shown to respond to physiological concentration of the primary BA 
chenodeoxycholic acid (CDCA) (Pellicciari et al. 2004a), as well as to lithocholic acid 
(LCA) and deoxycholic acid (DCA), but not to ursodeoxycholic acid (UDCA) and to 
regulate the expression of several genes controlling BA disposal through modulation of 
the cholesterol metabolism (Fitzgerald et al. 2002; Chawla et al. 2001). It has been 
demonstrated that FXR is involved in cholesterol catabolism, feedback inhibition of BA 
synthesis by repressing the expression of the CYP7A and CYP8B genes (Chen et al. 
2001) through increase in the level of the nuclear receptor SHP (Costantino et al. 2003; 
Lu et al. 2000) and by activating gene expression of the BA transporters I-BABP, 
BSEP, and MAOT (Willson et al. 2001). All this information about FXR makes it a 
particularly attractive target for the discovery of drugs for the treatment of cholestasis 
10 or hyperlipidemia (Francis et al. 2003).  
In 2003, Pellicciari et al (Costantino et al. 2003) reported the synthesis and the 
preliminary evaluation of a series of 6α-alkyl-substituted analogues of 
chenodeoxycholic acid (CDCA), among which 6α-ethyl-chenodeoxycholic acid (6α-
ECDCA called INT-747) turned out to be the most potent steroid agonist so far reported 
for the Farnesoid X Receptor (FXR) (Pellicciari et al. 2002). 
The relationship between structure and activity showed the existence of a small 
hydrophobic pocket in the receptor that can accommodate small alkyl groups at position 
6 of the ring steroid CDCA (in order of activity: ethyl 3> n-Propyl 4> Benzyl 5). The 
portion of ethyl in position 6 is stabilized in its hydrophobic pocket, consisting of 
Phe284, Thr288, Leu451 and Phe 461(Figure 1.6). On the other hand, the largest pocket 
(163 Å (Evans et al. 1988)) near the carboxylic group could easily guest the glycine (42 
Å (Evans et al. 1988)) and taurine (69 Å (Evans et al. 1988)) moieties of the glycol- and 
tauro- conjugates of CDCA. Indeed, it has been reported that the glycine and taurine 
conjugates of CDCA activate FXR in tissues that express BA transporters (IBAT) 
(Parks et al. 1999).  
 
	 14
 
Figure 1.6: Docking result of 6-ECDCA.(From Costantino et al. 2003) 
 
In the past decade (Fiorucci et al. 2009), many synthetic FXR agonists (summary in 
table 1.1) have been generated. GW4064, 6-ECDCA and fexaramine are synthetic FXR 
ligands with nanomolar potency (Maloney et al. 2000; Pellicciari et al. 2002; Downes et 
al. 2003; Mi et al. 2003). 
 
Table 1.1: FXR agonists 
NATURAL Biological effects 
CDCA Decreases the plasma levels of TG and HDL but increases those of 
LDL (Porez et al. 2012). 
LCA, DCA Decreases the plasma levels of HDL. (Porez et al. 2012). 
CA Decreases the plasma levels of TG (Porez et al. 2012). 
SYNTHETIC Biological effects 
Fexaramine (5) 
In vitro assays have established that fexaramine induces 
recruitment of the coactivator SRC-1 to FXR in a manner 
comparable to that observed for GW4064 (Downes et al. 2003). 
GW4064 (6) 
A non-steroidal ligand; its potential cell toxicity and uncertain 
bioavailability prevent its development for clinical studies. 
Decreases plasma TG and insulin resistance in ob/ob mice. 
6-ECDCA (1) 
Active in primary biliary cirrhosis.  
Decreases the plasma levels of TG and HDL but increases those of 
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LDL. (Porez et al. 2012) 
T0901317 
It is a weak FXR ligand that induces BSEP and SHP expression 
and is a potent LXR agonist (Houck et al. 2004). 
AGN43 
Reduces cholesterol plasma levels in animals (Dussault et al. 
2003). 
MeCA 
MeDCA 
NIHS700 
Activate FXR responsive genes in vitro but have not been tested in 
preclinical models (Suzuki et al. 2008). 
MFA-1 (7) 
It is nearly 500-fold more potent than CDCA and its activity on the 
receptor is comparable to that of GW4064. 
Binding to FXR is similar to that for steroid hormones (estrogens 
and glucocorticoids) (Soisson et al. 2008).  
XL335 ( or FXR450 or WAY-
362450) (8) 
Decreases serum triglyceride and cholesterol levels (Evans et al. 
2009). 
1) Intercept Pharmaceuticals®; 5) Amgen®; 6) GSK®; 7) Merck®; 8) Wyeth Research (Fiorucci et al. 
2009). 
 
The first synthetic BA analogue 6-ECDCA (INT-747) is now in the clinical phase 3 trial 
for the treatment of PBC and its trivial name is Obetic cholic acid (OCA). 
 
1.2.2. FXR antagonists and modulators 
 
The activation of FXR leads to a complex response that integrates beneficial actions and 
potentially undesirable side-effects (Fiorucci et al. 2009; Kast et al. 2001). 
The most important side effects that occurred with FXR agonists are:  
1) The inhibition of BA synthesis which might reduce cholesterol excretion (Fiorucci et 
al. 2009b); 2) The repression of ApoAI leading to a decrease in circulating levels of 
HDL (Sinal et al. 2000). Thus, identification of gene-selective FXR modulators 
(selective BA receptor modulators, SBARMs) might be required for the development of 
compounds targeting specific clusters of genes avoiding the above mentioned side 
effects (Pellicciari et al. 2005a).  
Some examples (Houten et al. 2006) are Guggulsterone (induces BSEP but exerts 
antagonistic effects on FXR-induced recruitment of SRC-1 (Urizar et al. 2002)), 
fexaramine and AGN34 that are gene-selective FXRα modulators, which means that 
	 16
they can affect the expression of various FXRα target genes in different ways 
(antagonists or agonists) (Cui et al, 2003; Downes et al, 2003; Dussault et al, 2003). 
 
1.2.3. TGR5 agonists 
 
Modern drug discovery has focused its efforts towards the development of potent and 
selective TGR5 agonists belonging to BA or non-BA classes due to the emerging roles 
of BA in the regulation of energy and glucose homeostasis as a ligand of TGR5 (Tiwari 
et al. 2009). The metabolic syndrome and related diseases including diabetes are in 
continuous growth in western countries and this stimulates research in this area (Pols et 
al. 2011). 
The key amino acids implicated in the binding of BA in the binding pocket of the two 
receptors (TGR5 and FXR) are not entirely conserved, which allows the development of 
different BA derivatives with differing degrees of selectivity. 
Screening of various modulators has allowed the development of a structure–activity 
relationship (SAR), indicating that these positions are important for potency and 
selectivity of BA at the TGR5 receptor (Sato et al. 2008): 
 
1) Chain length of the carboxylic acid head (shortening the chain length of BA 
derivatives reduces their potency on TGR). 
2) Substitution at the alpha position of the carboxylic acid (introduction of the S 
methyl group at the 23(S)-position of carboxylic acid increases potency and 
provides higher selectivity over FXR). 
3) Rigidity of the cyclic system (introduction of a double bond to the cyclic 
systems of BA provides rigidity to the molecular system and, therefore reduces 
binding to TGR5, suggesting a flexible and spacious binding pocket).  
4) The TGR5 receptor exhibits a highly conserved binding pocket with three 
hydrogen bond acceptors to anchor three hydroxyl groups of BA and a charged 
surface to bind with carboxylic acid groups.  
 
The unique structural features of BA, which provide potency and selectivity towards 
TGR5, can be divided into four parts (Figure 1.7 below). 
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Figure 1.7: TGR5 receptor interaction sites for binding of BA. (From Tiwari et al. 2009) 
 
Region TGR5 receptor interaction sites for binding of BA 
A 
A large pocket, which consists of negatively charged residues to 
accommodate oppositely charged functional groups of the BA.  
Neutral groups like alcohols decrease the potency of BA binding to the TGR5 
receptor. 
B 
A binding pocket large in size for TGR5 receptor (spans over C-22 and C-23) 
compared with FXR may be a reason why it is possible to achieve good 
selectivity. Pellicciari et al. have shown that the introduction of a small alkyl 
group at the C-23 position can be tolerated by TGR5 and provides selectivity 
against FXR (Pellicciari et al. 2007a). The pocket is enantiomerically specific 
for the S-isomer over the R-isomer. 
C 
This region is a large hydrophobic pocket, spanning C-6 and C-7 of the BA 
and hence tolerates alkyl (e.g. methyl, isopropyl) and fluoro substitution at C-
7. 
D 
This is a narrow pocket with hydrogen bond acceptor groups, spanning the C-
3 region. A hydroxyl (or ketone) group at C-3 anchors BA to the receptor 
through hydrogen bonds; removing these groups therefore decreases potency 
at TGR5. 
Others 
(i) hydrogen bonding at C-12  
(ii) an electrostatic interaction at the terminal of the carboxylic acid 
group of BA (Macchiarulo et al. 2008). 
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(Fiorucci et al. 2009) The development of TGR5 ligands has been so far BAed on 
exploitation of the structure of natural ligands (LCA, TLCA and oleanolic acid) 
(Maruyama et al. 2002; Kawamata et al. 2003; Pellicciari et al. , 2007; Katsuma et al. 
2005; Macchiarulo et al. 2008, Tiwari et al. 2009). The 23-alkyl-substituted and 6,23-
alkyl-disubstituted derivatives of CDCA, such as the 6α-ethyl-23(S)-methyl-CDCA 
(called INT-777), are potent and selective agonists of TGR5 (Pellicciari et al. 2007a; 
Macchiarulo et al. 2008) and methylation at the C23-(S) position of natural BA confers 
marked selectivity to TGR5 over FXR activation, whereas 6α-alkyl substitution 
increases the potency at both receptors (Pellicciari et al. 2007a; Macchiarulo et al. 
2008). In addition to these semi-synthetic steroidal TGR5 agonists, several synthetic 
non-steroidal TGR5 agonists are being developed (Table 1.2).  
 
Table 1.2: TGR5 agonists 
 
NATURAL Biological effects 
TLCA > LCA 
DCA 
CDCA 
CA 
Decrease the cytokine production in 
macrophages in vitro and increase the energy 
expenditure in mice (Porez et al. 2012). 
Oleanolic acid (4) 
Decreases the insulin resistance in DIO mice. 
Decreases colitis in mice (Porez et al. 2012). 
SYNTHETIC Biological effects 
6α-ethyl-23(S)-methyl-CA (1) 
Increases the energy expenditure and GLP-1 
release. Decreases the glucose intolerance in 
mice and atherosclerosis in LDLR-KO mice and 
choleretic action in mice (Porez et al. 2012). 
Quinazolinones (2) 
Induce GLP-1 secretion from GLUTag cells and 
increase insulin secretion and decrease glucose 
levels in mice ( Pinkerton et al.). 
Imidazol[1,2-α] [1,2]diazepin (2) Modulators of TGR5 ( Pinkerton et al.). 
Quinolines (2) Increase GLP-1 release and OGTT in DIO mice. 
BR27 (3) Decreases the Cytokine production in mouse 
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1) Intercept Pharmaceuticals; 2) Kalypsys; 3) Bayer AG; 4) Takeda Chemical Industries LTD; 5) Amgen; 
6) GSK; 7) Merck; 8) Wyeth Research 
 
There are several limitations of currently available steroidal TGR5 ligands because 
LCA is a toxic BA (Tan et al. 2007) and steroidal ligands have therefore been 
developed using the CA scaffold (i.e. the same strategy used to generate steroidal FXR 
ligands with CDCA). However, CDCA is not totally safe when administered to animals, 
and doses > 5 mg/kg increase AST and ALT in patients (Fiorucci et al. 2009a) but CA 
does not show this problem.  
Non-steroidal compounds have been poorly described and information regarding their 
efficacy is not conclusive. The main indication for the development of TGR5 agonists is 
for treatment of obesity to exploit the effect of the receptor in regulating energy 
expenditure. The mechanisms involved in regulation of energy expenditure in man, 
however, are likely to be more complex than those described in mice, even though 
human fat contains a significant amount of brown adipose tissue, the thermogenically 
active tissue preferentially targeted by TGR5 in the mouse (Kirsi et al. 2009).  
 
1.2.4. Dual Farnesoid X Receptor and TGR5 Agonist 
 
In the previous paragraphs it was reported that 6E-CDCA (INT-747) is a potent and 
selective FXR agonist, while 6Ethyl, 23Methyl(S)-CA (INT-777) is a potent and 
selective TGR5 agonist (Rizzo et al. 2010). 
During the development of these analogues it was found that other BA analogues 
exhibit a dual activity toward these two receptors. 
It was previously found that 6-ethyl-3,7,23-trihydroxy-24-nor-5-cholan-23-sulfate 
sodium salt (INT-767) a synthetic 23-sulfate derivative of INT-747 developed by 
Pellicciari’s group is a potent agonist for both FXR (EC50, 30 nM) and TGR5 (EC50, 
Kupffer cells (Porez et al. 2012). 
6-methyl-2-oxo-4-thiophen-2-yl-
1,2,3,4- tetrahydropyrimidine-5- 
carboxylic acid-benzeyl ester (4) 
Improves metabolic homeostasis, pancreatic 
insulin secretion and inflammation (Sato et al. 
2008.). 
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630 nM), the first compound described so far to potently and selectively activate both 
BA receptors.  
 
To summarize, the BA analogues acting as a ligand of FXR or TGR5 or for both of 
them can be interesting tools to develop future candidates for the therapy of different 
diseases. These analogues must, however, have the necessary physico-chemical 
properties and pharmacokinetics to deliver the molecules in the target organ. 
 
The main therapeutic perspective are summarized below: 
 
 
 
Addition studies are required to better define suitable animal models or cell-based 
systems to better predict these effects in humans. 
 
BA analogues are 
promising targets for: 
Treatment of dyslipidemia (Fiorucci et al. 2009). 
Cholesterol-related disorders. 
Obesity.  
Type 2 diabetes. 
Being tested against Nonalcoholic steatohepatitis NASH. 
Steroidal FXR ligands 
Cholestasis, hyperlipidemia and primary biliary cirrhosis. 
Decreases the plasma levels of TG and HDL but increases 
those of LDL. 
Steroidal TGR5 ligands 
Stimulate incretin (GLP-1) release and decrease blood 
glucose levels in vivo and thus hold promise for the 
treatment of obesity and type 2 diabetes. 
Dual TGR5/FXR 
ligands 
Could provide new opportunities in the treatment of 
complex metabolic disorders in which several target 
pathways are involved. 
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1.3.PHYSICO-CHEMICAL PROPERTIES OF BILE ACIDS  
 
The experimental evaluation of physico-chemical properties of BA analogues is 
particularly important since their pharmacokinetics and in general their biodistribution 
and metabolism are strongly related to their structure (Carey et al. 1981; Gurantz et al. 
1984; Carey et al. 1983). 
In previous papers it’s been demonstrated that minor structural modifications such as 
the number of hydroxyls, their position and orientation modify the physico-chemical 
properties and, as a consequence, many biological properties such as intestinal 
absorption, albumin binding and the interaction with other lipids such as cholesterol and 
phospholipids. 
The most relevant and peculiar properties of naturally occurring BA are their 
detergency and ability to form mixed micelles with phospholipids and cholesterol and 
other lipids in bile and this can be evaluated by experimentally measuring the Critical 
Micellar Concentration (CMC) of pure systems and even more complex ones. 
The structural modification is able to modify the lipophilicity and, as a consequence, 
their partition in a lipid domain and therefore the extent of their intestinal passive 
absorption. The ionization constant is another import property to study 
 
1.3.1. Critical Micellar Concentration  
 
BA (salts) self-associate to form micelles over a broad range of concentration, as 
compared to that of typical ionic detergents, since the pattern of association is more 
stepwise (dimers, tetramers) (Hofmann et al. 1984; Mukerjee et al. 1984). In the past, 
Roda et all (Roda et all., 1983) used a dynamic method for measuring surface tension 
BAed on a maximum bubble pressure principle to determine the CMC of a large 
number of BA. This work demonstrated that the structure of both the nucleus and the 
side chain influences the CMC. For the nucleus, the key factor influencing self-
association appeared to be the contiguous hydrophobic area (β face is shown in figure 
1.8). Any decrease in this hydrophobic area raised the CMC, such that BA in which 
both sides of the molecule were hydrophilic did not form micelles even at high 
concentrations. Decreasing the side chain length increased the CMC. Amidation with 
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glycine or taurine had little effect on the reduction of CMC values in respect to the C-24 
free BA: the polarity of the amide bond compensated for the increased length of the side 
chain caused by glycine or taurine. Natural BA possess relatively low CMC values (< 
10 mM) because of the striking asymmetry of their nuclear structure having all the 
hydroxyls on the same side and therefore facilitating the back-to-back micelles 
formation and because of their negative charged five Carbon atoms side chain.  
 
Figure 1.8: Molecular structure (a) and the scheme of amphipathic structure (b) salts. R: side chain of 
glycine and taurine; C: cholate; DC: deoxycycholate; CDC: deoxcholate; UDC: ursodeoxycholate; LC: 
lithocholateholate.(From Hofmann et al. 1988). 
 
1.3.2. Water solubility  
 
The solubility of a BA is mainly related to the nature of the solid state and to the 
possibility to ionize in water.  
In the case of ionizable molecules like unconjugated natural BA, the dissociation 
constant is the key parameter since the protonated form is usually almost insoluble 
while the ionized species is much more soluble (Fini et al. 1985). The solubility in the 
case of a weak acid increases with the pH according to the equation: 
St = S0 [1+10(pH-pKa)] 
Where St = [HA]+[A-] 
 S0 = [HA]  
The solubility of the protonated species were obtained by performing measurements at 
pH = 1 (at least two units below the pKa of the common carboxylated BA (pKa= 5) and 
even when amidated with glycine (pKa= 3.9). 
	 23
When used as a drug, the solubility affects both the release-dissolution of the drug from 
the formulation and its intestinal absorption after oral administration (Figure 1.9). When 
the drug is administered intravenously, the role of the solubility is even more critical 
because it can lead to precipitation of solids within the blood vessels with serious 
consequences. 
 
 
Figure 1.9: Factors affecting the rate of absorption of drug from the gastrointestinal tract (From Goole 
at al., 2010) 
 
1.3.3. Lipophilicity of the molecule: the value of LogP O/W  
 
The LogP O/W is an index of the lipophilicity of the molecule. It is calculated by means 
of an equilibrium distribution at a given pH of the molecule between two phases, 
consisting of water and 1-octanol. Historically, the use of 1-octanol was chosen because 
it reflects the behavior of the lipid components of cell membranes quite well in its 
properties, thus making it possible to simulate "in vitro" what would happen to a solute 
in its distribution between the external aqueous extract of living cell and the lipid layer 
on its membrane.  
The partition properties in two immiscible phases are usually described by the partition 
coefficient (P) which refers to a single chemical species and is distinct from the 
distribution coefficient (D) which is the ratio between the total concentration 
(protonated and ionized form) in the two phases (Roda et al. 1990a). 
Solutes that display some preference for the nonpolar phase (logP > 0) are termed 
lipophilic or hydrophobic, while solutes are classified as hydrophilic (lipophobic) when 
logP < 0. The terms lipophilicity and hydrophobicity are often considered synonymous. 
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Lipophilicity can be expressed as a function of bulk (excluded volume) and polarity of 
the solute. Hydrophobicity refers to the first of these two parameters and is due to Van 
der Waals and hydrophobic forces. Hence, lipophilicity = hydrophobicity - polarity 
(Van De Waterbeemd et al. 1987). The calculation of the intrinsic partition coefficient 
from the experimentally determined distribution coefficient requires accurate 
knowledge of the dissociation constants of the BA studied (Fini et al. 1982; Fini et al. 
1987). The general equation used for the calculation of logP from logD using this 
simplification is: 
LogP = LogD+Log(1+10pH-pKa) 
Since BA molecules with a significant lipophilic component (Roda et al. 1990a) is a 
predictable distribution in the non-polar phase (octanol) both of the protonated 
component that of the ionized. 
According to these findings, both ionized and protonated species must be considered to 
partition in the 1-octanol phase and, consequently, the distribution coefficient D which 
takes this into account, must be defined: 
           [HA]oct + [A-]oct 
D =  
             [HA]w + [A-]w 
 
where [HA] and [A-] are the concentrations of protonated and ionized species in 1-
octanol (oct) and water (w), respectively. Combining this equation with that relating to 
the dissociation constant of a weak acid is obtained: 
     P'HA [H+] + P’A Ka 
D =  
        [H+] + Ka 
 
where P’HA and P’A are the intrinsic partition coefficients or HA and A-, respectively, 
and K is the dissociation constant of the BA.  
 
1.3.4. Affinity binding to serum albumin  
 
The bioavailability of a drug is influenced by its binding and affinity for plasma 
proteins in two opposite way. The binding to protein reduces the fraction of free drug, 
potentially pharmacologically active. 
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On the other hand evidence has been presented that the uptake of BA similarly to fatty 
acids is mediated by a (a)specific receptor on the liver cell surface (Weisieger et al. 
1981; Roda et al. 1982). The existence of a receptor for albumin on the hepatocytes may 
be responsible for the efficient hepatic extraction of those molecules which are most 
tightly bound to the albumin (Cowen et al. 1975). 
The interaction of human serum albumin with BA (BA) has been previously studied by 
equilibrium dialysis technique using 3H- and 14C-labeled BA (Roda et al. 1982). In this 
article the authors showed that the affinity constant of a BA for albumin decreases with 
an increase in the number of hydroxy groups and also with the replacement of 7-
hydroxy by 7-keto groups. The affinity constant is similar for glycine and taurine 
conjugated BA, but is slightly higher for unconjugated than conjugated forms (Fini et al. 
1987; Aldini et al. 1982). Hepatocyte uptake of BA returning from the intestine is not 
100% efficient. The efficiency of hepatic uptake depends on the BA structure: 
trihydroxy > dihydroxy, and conjugated BA > unconjugated BA (Hofmann et al. 1994; 
Aldini et al. 1984). According to these data we expected that the new BA analogues will 
have difference in the binding with albumin and therefore in their pharmacokinetics. 
 
Lipophilicity
(LogPO/W)
pKa
Binding affinity with
serum albumin
Solubility (range
physiologic pH)
The interaction with serum proteins
regulates the transport and the 
hepatic uptake
Intestinal passive absorption. Body 
fluids distribution. Toxicity
Problems of formulation and 
solubility in the intestinal 
content (low pH)
BIOAVAILABILITY OF A DRUG DEPENDS:
PHYSIOLOGICAL pH 
VALUES: 2.0-9.0
CMC
Toxicity, membrane structure 
modification surface tension lowering 
capacity, interaction and aggregation 
with lipids, proteins
Figure 1.10: Significance of the physico-chemical properties. 
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1.4. AIM AND RATIONALE 
 
This thesis is part of a more general research activities carried out in the Professor Roda 
Laboratory in collaboration with Professor Pellicciari group at the University of Perugia 
and InterceptPharmaceuticals Company related to the study of new synthetic analogues 
of BA as potential new drugs. 
Although the literature covers numerous articles on the physical-chemistry properties, 
biochemistry, metabolism, physiology and pathophysiology of endogenous BA, many 
aspects are still unknown. One of the limitations for accurate biochemical and metabolic 
study is due to the complexity of the BA metabolism different from human and animal 
species resulting in a highly variable composition of BA in different organs and 
compartments of the enterohepatic circulation producing many metabolites at very low 
concentrations. The analytical characterization is therefore extremely difficult and time 
consuming. In order to investigate aspects of the physiology and pathophysiology of 
endogenous BA and the pharmacology of new synthetic analogues, the present work has 
been developed in two phases: 
- Development of analytical methods for studies of the physico-chemical properties of 
synthetic analogues in comparison with natural BA. Combined HPLC-Electrospray-
Mass Spectrometry with efficient chromatographic separation of all studied BA and 
their metabolites, identified the parent ion generated by ESI source have applied to the 
analysis of BA in matrices. 
- Study of the structure-activity in vivo of new synthetic analogues of CA and CDCA 
and their tauro and glyco-conjugates using suitable animal model consisting of a bile 
fistula rat. 
The analytical methods have been used for the characterization, by means of chemical-
physical measurement, of their behavior in aqueous solution with particular regard to 
detergency evaluated by experimentally measuring the Critical Micellar Concentration 
(CMC), lipophilicity evaluated experimentally by the LogP, water solubility and 
albumin binding of the new analogues in comparison with natural BA and previously 
studied analogues. 
The rationale for the study of synthetic analogues of CA and CDCA was to design 
compounds that are not only active on the target receptors but in part more 
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metabolically stable, such as resistant to intestinal bacterial 7-dehydroxylation 
responsible for the formation of potentially toxic metabolites. 
Another objective is to keep the hepatic uptake and intestinal absorption of these 
compounds efficient. 
The pharmacological screening of their activity toward the specific receptors was done 
by the group of Professor Pellicciari (Rizzo et al. 2010) as a first screening, before 
subjecting the molecules to additional characterization. Table 1.3 reports the data of 
activity (EC50) of these molecules to receptors FXR and TGR5; new candidates for a 
second level screening will be selected on the basis of these data.  
 
   *=AlphaScreen FXR; **= FRET (cAMP) NCI-H716 cells TGR5 
 
 
 
TGR5 and FXR potency 
EC50 (µM) BA activity 
TGR5 *Agonist potency (µM) FXR **Agonist potency (µM) 
Natural BA  
CDCA 30 13 
CA 40 NA 
LCA 0.58 20 
Synthetic analogues of 6-Ethyl-CDCA 
INT-747 15 0.15 
INT-855 0.56 11.8 
Synthetic sulphonate and sulphate analogue of 6-Ethyl-CDCA 
INT-767 0.63 0.03 
Synthetic carboxylated analogues of 6-Ethy-CA 
INT-777 0.9 > 100 
INT-1075 22.5 44 
Synthetic sulphonates and sulphate analogues of 6Ethyl-CA 
INT-1244 0.7 7.0 
INT-2021 1.1 3.0 
INT-2023 1.6 0.6 
Synthetic carboxylates analogues of containing a 16β- hydroxyl 
INT-1212 0.65 11.5 
INT-2024 1.2 55 
Taurine and glycine conjugated analogues 
T-INT-777 7 >100 
T-INT-1212 5.4 8 
G-INT-777 5.5 >100 
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The structural changes must however ensure that the molecule maintains optimum 
physico-chemical properties in terms of acidity, solubility, detergency and lipophilicity. 
As previously defined on the basis of extensive structure-activity relationship studies 
carried out in the laboratory. 
More recently, up to thirteen new synthetic analogues have therefore been synthesized, 
and studied in the last 6 years. They can be divided into two main groups: unconjugated 
and steroid modified BA and BA conjugated with taurine or glycine or pseudo-
conjugates (sulphonate and sulphate analogue).  
The first group includes derivatives modified by introducing in the steroidal ring an 
Ethyl group in position C-6 and / or a Methyl in position C-23. 
These derivatives were selected on the BA is of their potency toward the target receptor 
and on the mean time to increase the metabolic stability toward 7-dehydroxylation and 
side chain modifications including amidation or deamidation of the corresponding 
conjugated analogue. 
The second group consists of glyco-conjugates or tauro-conjugates of synthetic 
analogues or sulphonate and sulphate conjugates of synthetic analogues, in order to 
avoid both hepatic conjugation to obtain an efficient secretion of bile and high 
metabolic stability of these conjugates. 
These reference naturally occurring BA are cholic and chenodeoxycholic acid. 
In this thesis, the main physico-chemical properties of the more recently developed 
analogues were measured. The intestinal absorption, hepatic uptake and metabolism and 
biliary secretion of new molecules compared with the natural analogues were studied in 
the bile fistula rat model after intravenous infusion (iv) and duodenal infusion (id) 
administration.  
The new BA analogues studied are: INT-2021, INT-2023, INT-2024, T-INT-1212, T-
INT-777, INT-1057 and G-INT-777. The results were compared with those obtained in 
the previous years using the same experimental protocol in the laboratory of Professor 
Roda which included: INT-747 (Roda et al. 2008, 2011 report), INT-930 (Roda et al. 
2009 report), INT-767 (Roda et al. 2008, 2008a report), INT-777 (Roda et al. 2009, 
2009a report), INT-1244 (Roda et al. 2009 report), INT-1212 (Roda et al. 2009 report) 
and INT -855 (Roda et al. 2010 report). 
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All the molecules studied in this thesis and classified according to their chemical 
structure are summarized below. 
 
Synthetic analogues of 6-Ethyl-CDCA: 
 
OHHO
OH
O
INT-747 OHHO
OH
O
INT-855
OHHO
NH
O
O
INT-930  
 
Synthetic sulphonate and sulphate analogues of 6-Ethyl-CDCA: 
 
OSO3H
OHHO INT-767
OSO3H
OHHO INT-1213
 
 
Synthetic carboxylated analogues of 6-Ethy-CA: 
 
OH
OHHO
OH
O
INT-777
OH
OHHO
OH
O
INT-1075
 
 
 
 
 
 
 
 
	 30
Synthetic sulphonates and sulphate analogues of 6Ethyl-CA: 
 
OHHO
OH SO3H
INT-1244 OHHO
OH
OSO3H
INT-2023 OHHO
OH
OSO3H
INT-2021
 
 
Synthetic carboxylates analogues of CDCA and CA containing a 16β- hydroxyl: 
 
OHHO
OH
O
OH
INT-1212
OH
OHHO
OH
O
OH
INT-2024
 
 
Taurine and glycine conjugated analogues: 
 
OHHO
OH
O
NH
SO3H
T-INT-777 OHHO
OH
O
NH
OH
O
G-INT-777 OHHO
O
NH
OH
SO3H
T-INT-1212
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2. METHOD HPLC-ESI-MS/MS 
 
The quali-quantitative determination of BA is extremely complex because, in addition 
to numerous forms which are formed of the BA (free, glyco, tauro and sulphates 
conjugates), in some biological fluids such as blood, bile and urine, their concentration 
is extremely variable (Roda et al. 1995). 
The old methods reported in the literature before the introduction of High Performance 
Liquid Chromatography – Electrospray tandem mass spectrometry (HPLC-ES-MS/MS) 
for the analysis of the different forms of BA, include a clean-up step of the analytes 
from the biological matrix and complex group separation (free, tauro and glyco 
conjugates, sulphates), by anion exchange resins (Scalia et al. 1990; Scalia et al. 1990a) 
and analysed by HPLC only in those fluids with BA concentration at mmolar level. Gas 
liquid chromatography has been extensively used for the analysis of BA in serum at 
molar level however derivatization steps are required (hydrolysis of the amide bond and 
solvolysis of the ether sulphates and derivatization to methyl esters trisilil ethers, to 
make them thermostable and volatile) (Karlaganis et al. 1980; Almè et al. 1977). In the 
case of liquid chromatography their detection by spectrophotometer is insensitive and 
nonspecific as not presenting strong chromophore groups.. Methods may be used 
derivatization pre- or post-column formation of fluorescent derivatives (Cavrini et al. 
1993; Ishii et al. 1983) or other detectors (eg electrochemical, Kamada et al. 1982). 
Roda et al. (Roda et al. 1992) have developed a system using a universal detector to 
light scattering allows the revelation with equal sensitivity of BA both free and 
conjugated without the need for derivatization.  
The use of HPLC combined with mass spectrometry with Electrospray interfece open a 
new era in BA analysis offering the possibility to directly analyse all the BA form in 
any biological fluid or organ and all the previous methodology have been full replaced 
(Griffiths et al. 2013). 
In this work we have developed a new method for analysis of bile samples collected at 
different times during the iv and id experiments were analyzed to determine the 
concentration of the administered analogues and their main metabolites in bile. 
Using this method, the concentration of BA in the different samples admitted to the 
physico-chemical property screening project were analyzed (see Chapter 3). 
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2.1. Material and methods 
 
2.1.1. Chemicals 
 
Solvent: All solvents were of high purity analytical grade and used without further 
purification. All solvents were: Water LiChrosolv® for HPLC, Merck; Acetonitrile, 
LiChrosolv® for HPLC, Merck; Methyl alcohol RPE, Glacial acetic acid RPE, Carlo 
Erba Reagents. 
 
Analytical Equipment: The following equipment was used for the HPLC-ES-MSMS 
analysis: Vortex mixer, Heidolph; Pipettes Eppendorf, Gilson; Triple quadrupole mass 
spectrometer QUATTRO-LC (MICROMASS); WATERS ALLIANCE 2695 
separations module (solvent and sample management platform); HPLC Luna Phenyl-
Hexyl Column 4µm, 150 x 2.1 mm protected by a SecurityGuard Phenyl 4.0 x 2.0 mm 
i.d. guard column, both supplied by Phenomenex. 
 
Natural BA: Chenodeoxycholic acid (CDCA), glycochenodeoxycholic acid (G-CDCA) 
and taurochenodeoxycholic acid (T-CDCA), cholic acid (CA), taurocholic acid (T-CA) 
and glycocholic acid (G-CA) were purchased from Sigma (St. Louis, MO). All chemical 
structures are summarized in Table 2.1. 
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R1
R5
R2
H
R3
R6
H
R7
R4
 
 
 
Table 2.1: Natural BA. 
 
Natural BA C3-R1 C7-R2 C12-R3 C23-R4 C6-R5 C16-R6 C23-R7 
CA OH (α) OH (α) OH (α) -CO-OH H H H 
T-CA OH (α) OH (α) OH (α) -CO-NH 
(CH2)2SO3- 
H H H 
G-CA OH (α) OH (α) OH (α) -CO-
NH(CH2)COO- 
H H H 
CDCA OH (α) OH (α) - -CO-OH H H H 
T-CDCA OH (α) OH (α) - -CO-
NH(CH2)2SO3- 
H H H 
G-CDCA OH (α) OH (α) - -CO-
NH(CH2)COO- 
H H H 
 
Synthetic BA: The present work was carried out on the more recent BA analogues 
under study in the Bioanalytical laboratory that include: INT-2021, INT-2023, INT-
2024, T-INT-1212, T-INT-777, G-INT-777. Data regarding INT-777, INT-1212 and 
other INT analogues derive from previous studies.  
Internal standards used are 6-ECDCA (INT-747), its tauro- and glyco-conjugates.  
Pure crystalline powder of each compound were synthesized, and purified (purity>99 % 
as documented by HPLC-ES-MS-MS analysis) in the laboratory of Prof. Pellicciari 
(Institute of Pharmaceutical Chemistry, University of Perugia, Italy).  
All chemical structures are summarized in Table 2.2. 
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R5
R2
H
R3
R6
H
R7
R4
 
 
Table 2.2: Synthetic BA.  
 
2.1.2. Calibration curve 
 
Stock solutions were prepared in methanol at 1 mmol/l and working solutions were 
prepared by diluting appropriate volumes of the stock solution. The stock solution was 
stored in screw cap disposable glass tubes at approximately -20ºC. These stock 
solutions were further diluted with methanol to obtain working solutions containing all 
the BA studied for the individual experiments for administration in the rat and for 
samples from the physico-chemical properties. For purposes of quantification, 
calibration samples were prepared by adding the appropriate amount of the 
corresponding BA working solution to bile samples collected at time zero (before 
Synthetic BA C3-R1 C7-R2 C12-R3 C23-R4 C6-R5 (α) C16-R6 C23-R7 
INT-747 OH (α) OH (α) - -CO-OH -CH2CH3 H H 
INT-777 OH (α) OH (α) OH (α) -CO-OH -CH2CH3 H -CH3 (S) 
T-INT777 OH (α) OH (α) OH (α) -CO-
NH(CH2)2SO3- 
-CH2CH3 H -CH3 (S) 
G-INT777 OH (α) OH (α) OH (α) -CO-
NH(CH2)COO- 
-CH2CH3 H -CH3(S) 
INT-2021 OH (α) OH (α) OH (α) -CH-OSO3- -CH2CH3 H -CH3 (S) 
INT-2023 OH (α) OH (α) OH (α) -CH2-OSO3- -CH2CH3 H H 
INT-2024 OH (α) OH (α) OH (α) -CO-OH -CH2CH3 OH(β) H 
INT-1212 OH (α) OH (α) - -CO-OH -CH2CH3 OH(β) H 
T-INT-1212 OH (α) OH (α) - -CO-
NH(CH2)2SO3- 
-CH2CH3 OH(β) H 
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infusion of the analogue) and diluted with mobile phase 1:10 (v/v) or directly with 
mobile phase for the samples from the physico-chemical properties. INT-747 and its 
glyco- and tauro- conjugates were used as the internal standards respectively to quantify 
the free analogues and glyco- and tauro- conjugates. 
A 6-point calibration curve was prepared daily. Calibration samples were obtained in 
the 0.1 to 20 μmol/l concentration range prepared in the bile matrix diluted (1:10 v/v 
with mobile phase) and only in mobile phase. Quality control (QC) samples were 
prepared at three concentrations, starting from the working solutions used for the 
calibration curve: low level: 0.3 μmol/l, medium level: 8.0 μmol/l and high level: 17.5 
μmol/l. At each day of analysis, the three concentrations of QC samples were assayed in 
duplicate.  
 
2.1.3. Sample preparation  
 
Bile samples  
Rat bile samples were brought to room temperature, briefly stirred, and diluted 1:1000, 
1:100 or 1:10 (v/v) (bile samples from femoral infusion and from duodenal infusion) 
with ammonium acetate buffer 15 mM pH 8 and acetonitrile : methanol (3:1 v/v) in 
ratio 65:35= aqueous solvent: organic solvent (v/v). The final solution was transferred 
to an autosampler vial and 5 µL was injected onto the chromatographic column. When 
samples were found to be outside the linearity range, they were diluted and reanalyzed. 
 
Samples from the physico-chemical properties 
The samples from Ws, LogP(A-) and albumin binding were brought to room 
temperature and diluted 1:100 or 1:10 (v/v) with ammonium acetate buffer 15 mM pH 8 
and acetonitrile : methanol (3:1 v/v) in ratio 65:35= aqueous solvent: organic solvent 
(v/v). The final solution was transferred to an autosampler vial and 5 µL was injected 
onto the chromatographic column. When samples were found to be outside the linearity 
range, they were diluted and reanalyzed. 
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2.1.4. Quantification 
 
Calibration curves were generated by plotting the peak area ratio of the respective 
compound to the corresponding internal standard versus the nominal concentration. The 
line of best fit was determined by linear-weighted (1/x) least-squares regression. The 
linearity acceptance criterion for the correlation coefficient was 0.99, or better. Each 
back calculated standard concentration should be within ± 15% deviation from the 
nominal value, except for the LLOQ, for which the maximum acceptable deviation was 
± 20%. 
 
2.1.5. Instrumentation: HPLC-ES-MS/MS analysis 
 
Rat bile samples (see Chapter 4) and samples of the physico-chemical property studies 
(see Chapter 3) were analyzed by liquid chromatography using a 2695 Alliance system 
(Waters, Milford, MA) separation module coupled with autosampler. The autosampler 
was maintained at 7°C. The analytical column was a Luna Phenyl-Hexyl (150x2.0mm 
i.d., 4 µm particle size), protected by a SecurityGuard Phenyl 4 x 2.0 mm i.d. guard 
column, both supplied by Phenomenex. BA were separated in elution gradient using 15 
mM ammonium acetate buffer (pH = 8.00) as mobile phase A and acetonitrile : 
methanol = 75:25 v/v as mobile phase B. The analysis was performed in the gradient 
mode, according to the following gradient table. 
Table 2.3: Elution gradient 
Time (min) A% B% Flow (ml/min) Curve 
0.00 65 35 0.150 1 
10.00 65 35 0.150 1 
10.30 55 45 0.150 6 
21.00 55 45 0.150 1 
21.30 0 100 0.150 6 
23.30 0 100 0.150 1 
24.00 65 35 0.150 6 
35.00 65 35 0.150 1 
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Solvents A and Solvent B were previously filtered using a 0.45 µm Millipore filter. 
Elution was performed at a flow rate of 0.15 ml/min. Sample injection volume was 5 µL 
and the column was maintained at 45°C. 
The HPLC was connected to a Quattro-LC (triple quadrupole of MicroMass) MS 
system operating with an electrospray (ES) ionization source in the negative mode with 
the following parameters. 
 
Table 2.4:Tuning parameters optimized 
Instrumental parameters Value 
Capillary: 3.0 KVolts 
Cone: 
60 volts Free-BA 
40 volts Glyco-BA 
70 volts Tauro-BA 
Extractor: 1 volts 
RF lens: 0.50 volts 
Source block temp.: 120ºC 
Desolvation temp.: 180ºC 
MS 
Entrance: 1.0 volts 
Exit: 1.0 volts 
Ion energy: 1.5 volts 
LM resolution: 12.0 
HM resolution: 12.0 
MS2 
Ion energy: 3.0 volts 
LM resolution: 12.0 
HM resolution: 12.0 
Pressure 
Analyser vacuum: 3.4e-5 mBar 
Gas cell: 2.6e-3 mBar 
Flows 
Nebulizer (Nitrogen): 87 lit/hr 
Desolvation gas (Nitrogen): 800 lit/hr 
Multiplier 650 volts 
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Instrument optimization was performed by direct infusion and manual tuning of each 
BA. Chromatograms were acquired using the mass spectrometer in multiple reaction 
monitoring (MRM) mode. Collision energies (by Argon) were performed for each BA. 
MassLynx software version 4.0 was used for data acquisition and processing. In 
addition, using mass spectrometry both in single MS and tandem MS/MS 
configurations, experiments were performed to identify metabolites. 
 
2.1.6. Identification of the metabolites 
 
Potential or expected metabolites including those conjugated with sulphate, glucuronic 
acid or dehydroxylated, decarboxylated, oxo and epimer derivatives (epimers have the 
same m/z ratio but often different retention time) were investigated, even if the 
standards necessary for their quantization were not available. These compounds were 
identified according to the m/z values.  
The table below summarizes some rules for studying the metabolism of BA. 
 
General rules for the identification of BA metabolites in mass 
spectrometry 
Acquisition 
mode 
Metabolite [M-H]-0 < [M-H]-1 SIR 
Conjugated species [M-H]-0 > [M-H]-1 MRM/SIR 
Analogues [M-H]-0 ~ [M-H]-1 MRM 
Interpretation 
of the profiles 
for in vivo 
experiments: Isomers [M-H]-0 = [M-H]-1 MRM/SIR 
Taurine-conjugated [M-H]-0 + 107 MRM 
Glycine-conjugated [M-H] -0 + 57 MRM 
Glucuronide-conjugated [M-H]-0 + 176 MRM/SIM 
Sulphate-conjugated [M-H]-0 + 80 SIM 
Dehydroxylated-derivatives [M-H]-0 - 16 SIM 
Decarboxylated-derivatives [M-H]-0 - 44 SIM 
Examples: 
Oxo-derivatives [M-H ]-0 - 2 SIM 
[M-H]-0=ion of the compound studied; [M-H]-1=ion of the Metabolite/Analogue/Conjugated/Isomer 
 
Taurine and glycine conjugates were identified in tandem mass spectrometry by 
monitoring the specific ion transitions in MRM mode (in this mode both quadrupoles 
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are fixed to detect one selected precursor ion and one, or more, selected product ions 
produced in the collision cell. The instrument does not make a full scan of all ions but 
only those of interest to us and this increases the sensitivity Figure 2.1). 
 
 
Figure 2.1: MRM analysis on QQQ MS. Several analytes are coeluting from the chromatographic system. 
The specific m/z selection in the first quadrupole filters out most coeluting ions. However, owing to 
identical mass, one interfering ion (blue) remains. In quadrupole 2, the analytes are fragmented. The m/z 
selection in the third quadrupole filters out all the fragments of the blue analyte and leaves only a 
particular fragment of the green analyte for specific detection (From Lange et al. 2008). 
 
All other conjugates were monitored in tandem mass spectrometry in a selected-ion 
reaction (SIR) mode with a negative electrospray ionization (ESI) interface by the 
following ions (rules summarized in the Table above). The metabolism results of each 
BA are described in section 4.1.2. 
In some experiments the glucuronide conjugates were identified also in tandem mass 
spectrometry (in MRM mode) by monitoring the specific ion transition m/z [M-H]- → 
175 (transition representative of glucuronide conjugate, there are other specific 
fragments from the spectra of glucuronide group they are 113, 85, 75 m/z but in our 
case the mass peak m/z 175 was more intense that other) in bile sample only diluted 
1:10 (v/v) in mobile phase. In addition, setting a lower cone voltage value (35 V), the 
double charged ion would be recorded.  
HO R2
O
O
R1
H
O
O
OH
OH
OH
OH
H  
As a test of the presence of the glucuronide conjugate were also made tests using the 
enzyme β-glucuronidase (fron Sigma Aldrich used for the enzymatic hydrolysis of 
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glucuronides prior to analysis) and treatment the sample with and without the enzyme in 
order to see if the signals of Free form or Glucuronidase form will change. That is, in 
the sample with the enzyme will increase the signal of the free form of BA (monitored 
in MRM mode) and will drop the signal glucuronide (monitored in MRM and SIR 
depends on the case and the complexity of the chromatographic profiles obtained). So in 
this case we can confirm the presence of glucuronide form. 
 
2.1.7. Method validation 
 
In terms of linearity, accuracy and precision, the bioanalytical method used in this study 
fulfils the compliance criteria described by the FDA Guidance for the industry: 
bioanalytical method validation. 
The limit of quantification (LOQ) of the different analytes was calculated using a 
signal-to-noise ratio of 5 from data obtained for spiked bile samples diluted 1:10 (v/v) 
with mobile phase. In addition, the coefficients of variation at this concentration were 
calculated for each BA. The limit of detection (LOD) of the different analytes was 
calculated using a signal-to-noise ratio of 3 from data obtained for spiked bile samples 
diluted 1:10 (v/v) with mobile phase.  
Each back calculated standard concentration should be within ±15% deviation from the 
nominal value, except for the LOQ, for which the maximum acceptable deviation was 
±20%. 
lntra-day and inter-day precision and accuracy were determined by analyzing individual 
BA in three different QCs corresponding low (0.3 μmol/l), medium (8.0 μmol/l) and 
high (17.5 μmol/l) representative concentrations.  
The IS concentration (1 μmol/l for INT-747, T-INT-747 and G-INT-747) was 
maintained constant in all the QCs. Each QC was analyzed five times in three different 
experimental sample batches. The acceptance criteria for precision within and between 
batches, expressed as a coefficient of variation (CV), were ±20% for the LLOQ and 
±15% or better for the other concentrations. Accuracy is expressed as the relative 
measurement error (RME) and was calculated using the following formula: RME (%) = 
100 x (calculated concentration - nominal concentration)/nominal concentration. The 
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acceptance criteria were ±20% for within and between batches for the LLOQ and ±15% 
or better for the other concentrations. 
The biological matrices contain numerous endogenous substances that may interfere 
with analysis and generate a matrix effect if coelute with the analyte resulting decrease 
(ion suppression) or increase instrumental response. The matrix effect was calculated as 
the ratio of the analyte in mobile phase with respect to the analyte in the bile sample 
(collected at time zero and diluted 1:10 (v/v) with mobile phase) fortified at the end of 
the process. The total recovery was not determined because the sample pretreatment is 
only a dilution of bile sample and not an extraction or clean-up procedure as for samples 
from the physico-chemical properties. 
 
2.2. Results and Discussion 
 
2.2.1. Optimization of chromatographic conditions 
 
The optimization of the chromatographic analysis for all analytes is based on the peak 
resolution , the retention time , analysis time and the need to obtain the highest signal-
to-noise (S/N); a suitable pH value and a suitable solvent for the mobile phase were 
therefore evaluated. 
The best result in terms of ESI response, resolution of peak and time of 
chromatographic run is obtained with a Luna Phenyl-Hexyl (150x2.0mm i.d., 4 µm 
particle size) hydrophobic column ideal for the retention of acids, protected by a 
SecurityGuard Phenyl 4 x 2.0 mm i.d. guard column, both supplied from Phenomenex.  
BA were separated in elution gradient using 15 mM ammonium acetate buffer (pH = 
8.00) as mobile phase A and acetonitrile : methanol = 75:25 v/v as mobile phase B. In 
analytical conditions optimal retention times average (n = 20) are reported in the 
following table 2.5. 
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Table 2.5: Retention times of the different BA 
 
BA Free- BA Glycine - BA Taurine - BA 
 tR  tR  tR 
CA 6  6.4  7.1  
CDCA 12.8  11.8  13.8  
INT-747(IS) 23.3  21.9  20.9  
INT-777 10.3  7.5  8.7  
INT-1212 8.3 NA 10.5  
INT-2021 16.6 NF NF 
INT-2023 21.9 NF NF 
INT-2024 5.4 NF 6.4* 
NA= not available; tR= minutes; NF= not formed; *= not standard available 
 
It was possible to use the same matrix , with bile collected before the infusion in the rat 
diluted 1:10 (v/v) with mobile phase, to plot the calibration curve because the BA that 
we analyse are synthetic BA, with structural modifications, that are not found in this 
sample. To quantify TCDCA and CDCA, we had no problems since TCDCA and even 
the free form CDCA are almost absent in the rat bile and therefore the signals are 
negligible compared to those found after the administration of these compounds. 
The conditions of "purge" of the column and reconditioning guarantee the stability of 
the pressure of the chromatographic column and as well as repeat times reproducible 
(standard deviation of time retention is ± 0.1 min. for each BA studied) for at least 50 
consecutive injections. 
The injection volume of 5µl was chosen as the optimum volume in terms of peak 
amplitude, signal-to-noise ratio and stability of the system during an analysis cycle 
(lasting 42 hours). 
Figures 2.2 and 2.3 show a typical chromatogram obtained in MRM mode acquisition 
from analysis of bile sample containing 10 µM of the respectively reported analytes, IS 
in bile matrices diluted 1:10 with mobile phase and blank bile samples in matrix.  
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Internal standards (INT-747, T-INT-747 and G-INT-747 1 uM)
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Figure 2.2: Example of RIC chromatogram (acquired in MRM mode) obtained from the analysis of bile 
(taken prior to infusion of the synthetic BA) diluted with mobile phase and after spiking with ISs (INT-
747,T-INT-747 and G-INT-747 at the concentration of 1 µM) used to build the calibration curve.  
 
 
Point 5 of the calibration curve of synthetic analogues 
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Figure 2.3: Example of RIC chromatogram (acquired in MRM mode) obtained from the analysis of bile 
(taken prior to infusion of the synthetic BA) diluted with mobile phase and after spiking with synthetic 
analogues (at the concentration of 10 µM) used to build the calibration curve.  
 
Table 2.6 reports the values of intensity of the chromatographic peaks expressed as eV 
obtained from the chromatographic run, in matrix. This is equivalent to point five of the 
calibration curve. 
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Figure 2.4: Example of blank chromatogram (acquired in MRM mode) obtained from the analysis of bile 
(taken prior to infusion of the synthetic BA) diluted with mobile phase used to build the calibration curve. 
RIC= reconstitute ion current (of all analogues searched). 
 
 
 
Synthetic analogues 
Chromatogram peak 
intensity at [C]= 10 µM 
INT-2024 6.49E+04 
INT-2021 8.60E+04 
INT-2023 5.72E+04 
INT-1212 1.82E+05 
T-INT-1212 2.35E+06 
INT-777 1.54E+06 
T-INT-777 1.07E+05 
G-INT-777 2.03E+04 
INT-747 9.53E+06 
T-INT-747 6.28E+04 
G-INT-747 4.89E+05 
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2.2.2. Optimization of mass spectrometry conditions 
 
The mass spectrometry optimization is obtained by evaluating both ionization modes 
and the effect of different compositions of the mobile phase to find the optimal 
conditions for the ESI source.  
The use of solvents containing weak acids usually leads to a higher signal-to-noise ratio, 
but in this case of BA a better signal is obtained using a basic pH. Instrument 
optimization was performed by direct infusion (conditions of infusions: flow rate = 40 
µl/min; Solutions = 0.02 mM in 50:50 (v/v) = buffer : organic solvent (acetonitrile : 
methanol = 75:25 (v/v)) and manual tuning of each BA, a summary table 2.7 of the 
compound infusions is shown below.  
 
Table 2.7: BA and their ions used in the HPLC–ESI-MS/MS analysis. 
BA Free- BA  Glycine - BA  Taurine - BA  
 P.I. [M-H]- →product ion (m/z) CE 
P.I. [M-H]- 
→product ion (m/z) CE 
P.I. [M-H]- 
→product ion (m/z) CE 
CA 407→407 15 464→74 40 514→80 60 
CDCA 391→391 15 448→74 40 498→124 50 
INT-747(IS) 419→419 20 476→74 40 526→107 60 
INT-777 449→449 15 506→74 60 556→80 60 
INT-1212 435→435 15 492→492 15 542→542 15 
INT-2021 501→501 5 NA - NA - 
INT-2023 487→487 5 NA - NA - 
INT-2024 451→451 5 NA - 558→124* 40 
P.I. = Precursor ion; CE= collision energy; NA = not available; IS= internal standards; *=not standard 
available 
 
The figures below report some examples of MS/MS mass spectra of INT-777, CA, T-
INT-777, T-CA, G-CA and G-INT-777 compounds acquired after instrument 
optimization.  
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MS/MS spectrum of G-CA
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The value of the intensity reported in the different MSMS spectra ( in eV) suggests that 
the structural modifications performed on the new BA analogues, compared to the 
natural BA, do not affect the ionization with a similar response in ESI source both free, 
glycine and taurine BA. 
 
2.2.3. Method validation 
 
The HPLC-ES-MS/MS method was validated in terms of accuracy, precision and 
linearity. Overall accuracy and precision were appropriate for all the determinations.  
The average recovery due to the effect matrix for all analytes is 97% while for the 
internal standards are 100% (CV% < 2), thus confirming the absence of the matrix 
effect in optimized conditions. 
Table 2.8 shows the parameters for the calibration curve derived from the statistical 
analysis of six calibration curves (obtained in duplicate) obtained in bile matrix.  
 
Table 2.8: Parameters for the calibration curve obtained for each BA. 
 
The calibration curves show good linearity in the range of concentration between 0.1 
and 20 µM. This concentration range proved to be suitable for analyzing both the bile 
samples appropriately diluted with mobile phase (1:1000, 1:100 and 1:10 v/v) that the 
BA Slope (± sd) Intercepts (± sd) R2  IS 
G-INT-777 6.64E-04±1.2E-04 5.88E-03±2.3E-03 0.992 G-INT-747 
T-INT-777 1.65E-04±0.3E-04 -3.85E-04±2.2E-04 0.993 T-INT-747 
INT-777 2.83E-03±0.8E-03 1.87E-02±0.4E-02 0.995 INT-747 
T-INT-1212 2.36E-04±1.1E-04 -6.48E-03±2.0E-03 0.997 T-INT-747 
INT-1212 1.56E-07±0.4E-07 -1.60E-04±0.4E-04 0.999 INT-747 
INT-2021 3.05E-04±0.8E-04 -8.32E-02±3.0E-02 0.997 INT-747 
INT-2023 1.89E-04±0.7E-04 -2.06E-02±1.0E-02 1.000 INT-747 
INT-2024 5.62E-05±2.0E-05 2.58E-02±0.9E-02 0.993 INT-747 
T-CDCA 5.57E-04±1.8E-04 -4.35E-03±1.3E-03 0.997 T-INT-747 
CDCA 5.78E-04±3.2E-04 1.15E-03±0.5E-03 0.995 INT-747 
T-CA 8.09E-04±3.2E-04 9.21E-03±0.5E-03 0.996 T-INT-747 
CA 7.62E-04±3.2E-04 -1.45E-02±0.3E-02 0.996 INT-747 
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samples of the physico-chemical properties because the method don't shows the matrix 
effect and so the validation parameters obtained in the mobile phase or in bile diluted, 
as matrix, did not change the values of precision, accuracy and linearity. 
Therefore we performed calibration curves in mobile phase for the samples of the 
physico-chemical properties and in bile diluted for bile samples from rat. 
lntra-day and inter-day accuracy, measured as RME, ranged from -7.7% to 8.0%. 
Precision, measured as CV (%), was below 10.0% and 9.4% for intra- and inter-day, 
respectively (Table 2.9). In terms of linearity, the regression coefficients for all the 
calibration curves of the BA were higher than 0.992.  
 
Table 2.9:The precision, accuracy for each BA. 
 
Precision is expressed as a coefficient of variation (%). Accuracy is expressed as the relative error 
(RME) and is calculated using the following formula: RME (%)=100x(calculated concentration – 
nominal concentration)/nominal concentration. L: low concentration (0.3 μmol/l; M: medium 
concentration (8.0 μmol/l); H:high concentration (17.5 μmol/l). 
 
 
lntra-day Validation lnter-day Validation 
BA 
Precision (cv%) Accuracy (RME %) Precision (cv%) Accuracy (RME %) 
 L M H L M H L M H L M H 
CDCA 2.4 5.2 6.2 2.1 -0.5 1.3 3.2 3.4 2.3 1.1 -0.7 1.2 
T-CDCA 3.8 3.1 3.3 0.1 6.3 2.2 3.2 2.6 3.3 0.1 6.2 1.1 
G-CDCA 5.0 7.0 2.0 2.8 2.6 5.0 7.0 2.0 6.0 1.8 1.6 5.0 
CA 2.1 9.4 1.7 0.7 0.3 4.2 5.2 3.3 9.4 0.4 0.2 4.1 
T-CA 5.6 3.8 1.4 5.2 -0.7 1.4 3.8 2.6 3.8 5.1 -0.4 1.4 
G-CA 1.2 .1.7 4.7 0.4 3.5 -2.6 .2.7 3.3 .3.6 0.4 2.5 -1.6 
INT-777 7.8 2.4 2.5 1.8 2.7 0.2 2.2 6.8 3.4 1.8 1.4 0.1 
T-INT-777 10 2.6 2.8 1.2 4.1 0.8 2.6 30 3.6 1.1 4.1 0.8 
G-INT-777 7.0 1.3 4.8 4.4 2.2 2.5 2.3 6.0 3.3 4.4 1.1 1.5 
INT-1212 4.5 5.0 9.0 2.8 3.7 1.1 3.0 4.2 2.0 1.8 2.4 1.1 
T-INT-1212 2.0 7.3 6.8 -0.2 2.2. 3.2 7.3 3.0 6.3 -0.1 1.1. 2.1 
INT-2021 5.7 2.1 4.7 2.2 5.6 -0.6 2.2 2.6 3.3 1.1 5.6 -0.6 
INT-2023 5.8 2.5 3.3 3.1 -7.7 5.0 2.3 2.8 3.2 2.1 -4.4 5.0 
INT-2024 1.6 6.1 2.3 1.1 8.0 4.9 6.2 3.6 6.3 1.1 8.0 4.9 
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The LOQ values (signal-to-noise ratio, 5) for bile samples were between 0.005 and 0.01 
μM. The LOD values (signal-to-noise ratio, 3) for bile samples were between 0.001 and 
0.02 μM. The following are the values of LOD and LOQ for each BA analyzed (Table 
2.1.0.). 
 
Table 2.1.0: Limit of quantification and Limit of detection (μM) of the different BA. 
 
BA LOQ (μM) LOD (μM) BA LOQ (μM) LOD (μM) 
CDCA 0.01 0.002 INT-777 0.005 0.001 
T-CDCA 0.01 0.003 T-INT-777 0.007 0.003 
G-CDCA 0.01 0.0004 G-INT-777 0.01 0.003 
CA 0.01 0.003 INT-1212 0.01   0.002 
T-CA 0.01 0.003 T-INT-1212 0.01 0.01 
G-CA 0.01 0.003 INT-2021 0.01 0.003 
INT-747 0.04 0.01 INT-2023 0.01 0.003 
T-INT-747 0.09 0.02 INT-2024 0.01 0.004 
G-INT-747 0.09 0.02    
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2.2.4. Pharmacokinetics (biliary secretion) and hepatic metabolism of 
the administered analogues: iv and id infusion. 
 
The data refer to the samples from the physico-chemical properties are summarized in 
chapter 3 sections 3.2.2. for Ws, 3.2.3. for LogP(A-) and 3.2.4. for albumin binding. 
The data refer to the secretion rate of the more recent BA analogues recovered in bile as 
such after duodenal and femoral infusion at a dose of 1 µmol/min/kg (Tables 2.1.1, 
2.1.2, 2.1.3 and 2.1.4). 
 
Table 2.1.1: INT-2021, INT-2023, and INT-2024 concentrations in µmol/l and secretion 
values in µmol/min/kg obtained from rat bile samples collected during the duodenal 
infusion (1 hour ranging from 75 to 135 minutes). 
 
Time INT-2021 (n=3) INT-2023 (n=3) INT-2024 (n=3) 
(min) Conc.±SD Secretion±SD Conc.±SD Secretion±SD Conc.±SD Secretion±SD 
ID (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) 
75 n.d. - n.d. - n.d. - 
90 3.0±2.0 0.00011±0.00007 1.8±0.8 0.00008±0.00001 4.78±0.01 0.0002+0.0002 
105 6.0±1.0 0.00011±0.00001 24±3 0.0012±0.0001 92.24±0.01 0.004±0.004 
120 21±7 0.0003±0.0002 120 ±20 0.0063±0.0008 400±100 0.020±0.006 
135 16.0±7.0 0.0007±0.0002 378±3 0.0186±0.0002 800±200 0.036±0.007 
150 23.0±9.0 0.0006±0.0003 920±30 0.044±0.002 800±400 0.036±0.003 
165 70±20 0.0008±0.0006 1200±100 0.057±0.005 1200±600 0.08±0.01 
180 110±20 0.004±0.001 1000±400 0.05±0.02 860±90 0.036±0.003 
195 77±6 0.0030±0.0002 7000±300 0.04±0.02 770±80 0.03±0.03 
210 60±20 0.0002±0.0006 700±100 0.037±0.007 420±70 0.017±0.005 
225 72±7 0.0022±0.0002 500±0.3 0.03±0.02 270±50 0.011±0.003 
240 70±30 0.0022±0.0009 500±0.3 0.03±0.01 130±30 0.005±0.004 
255 60±40 0.002±0.001 500±0.4 0.02±0.02 140±70 0.006±0.005 
n.d.= not detected; - = not calculated 
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Table 2.1.2: T-INT-777, G-INT-777, and T-INT-1212 concentration and secretion 
values obtained from rat bile samples collected during the duodenal infusion (1 hour 
ranging from 75 to 135 minutes). 
 
Time T-INT-777 (n=3) G-INT-777 (n=3) T-INT-1212 (n=3) 
(min) Conc.±SD Secretion±SD Conc.±SD Secretion±SD Conc.±SD Secretion±SD 
ID (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) 
75 n.d. - n.d. - n.d. - 
90 5.0±1.0 0.030±0.005 0.2±0.1 0.001±0.001 n.d. - 
105 6.0±1.0 0.030±0.008 0.9±0.2 0.005±0.003 0.3±0.1 0.001±0.001 
120 7.0±1.0 0.04±0.01 2.0±1.0 0.008±0.004 2.5±0.5 0.008±0.001 
135 11.0±3.0 0.06±0.01 100±20 0.66±0.02 4.0±1.0 0.014±0.003 
150 19.0±4.0 0.13±0.02 3.0±0.2 0.50±0.04 5.0±1.0 0.020±0.002 
±165 10.0±2.0 0.11±0.06 2.5±0.5 0.10±0.02 3.3±0.8 0.020±0.002 
180 14.0±5.0 0.10±0.03 3.3±0.6 0.03±0.01 4.8±0.9 0.016±0.003 
195 11.0±2.0 0.100±0.005 2.5±0.8 0.012±0.002 2.5±0.5 0.013±0.006 
210 20.0±3.0 0.100±0.003 2.1±0.5 0.008±0.003 2.5±0.7 0.012±0.004 
225 20.0±6.0 0.09±0.01 2.3±0.3 0.008±0.006 3.6±0.8 0.012±0.002 
240 20.0±3.0 0.080±0.005 3.5±0.2 0.015±0.003 3.5±0.7 0.012±0.002 
n.d.= not detected; - = not calculated 
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Table 2.1.3: INT-2021, INT-2023, and INT-2024 concentration and secretion values 
obtained from rat bile samples collected during the femoral infusion (1 hour ranging 
from 75 to 135 minutes). 
 
Time INT-2021 (n=3) INT-2023 (n=3) INT-2024 (n=3) 
(min) Conc.±SD Secretion±SD Conc.±SD Secretion±SD Conc.±SD Secretion±SD 
IV (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) 
75 n.d. - n.d. - n.d. - 
90 n.d. - 50±30 2.02±0.03 n.d. - 
105 6900±2900 400±200 6511.3±0.7 300±200 13700±200 720±9 
120 10800±3600 0.79±0.05 11900±5200 0.5±0.1 17200±1700 0.88±0.09 
135 9100±3500 0.5±0.2 14400±2900 0.69±0.04 18800±800 1.00±0.08 
150 6300±6200 0.3±0.2 14300±1200 0.69±0.04 19300±40 0.923±0.002 
165 7300±4200 0.3±0.2 10100±1000 0.52±0.04 4100±2400 0.2±0.1 
180 7400±900 0.3±0.2 3900±800 0.3±0.2 1500±1100 0.07±0.05 
195 4700±600 0.2±0.1 1100±300 0.07±0.03 900±600 0.04±0.03 
210 1100±1000 0.04±0.03 480±50 0.028±0.006 500±400 0.02±0.02 
225 1600±900 0.05±0.04 200±100 0.0130±0.0009 300±200 0.02±0.01 
240 680±70 0.02±0.01 170±10 0.0098±0.0004 200±100 0.010±0.007 
255 500±400 0.010±0.009 148±7 0.0084±0.0003 140±90 0.006±0.004 
n.d.= not detected; - = not calculated 
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Table 2.1.4: T-INT-777, G-INT-777, and T-INT-1212 concentration and secretion 
values obtained from rat bile samples collected during the femoral infusion (1 hour 
ranging from 75 to 135 minutes). 
 
Time T-INT-777 (n=3) G-INT-777 (n=3) T-INT-1212 (n=3) 
(min) Conc.±SD Secretion±SD Conc.±SD Secretion±SD Conc.±SD Secretion±SD 
IV (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) (µmol/l) (µmol/min/kg) 
75 n.d. - n.d. - n.d. - 
90 60±10 0.48± 0.07 99.0±2.0 0.72±0.05 100±20 0.66± 0.01 
105 160±20 0.93±0.10 113.0±2.0 0.83±0.07 140±30 0.96± 0.06 
120 170±30 0.98±0.07 140±10 0.98±0.05 150±50 0.91± 0.07 
135 20.0±1.0 0.11±0.05 2.0±1.0 0.20±0.05 110±10 0.50± 0.08 
150 6.0±1.0 0.020±0.005 22.0±2.0 0.09±0.06 20±10 0.12± 0.02 
165 4.0±1.0 0.020±0.005 7.0±0.2 0.040±0.001 10±1.0 0.04± 0.01 
180 2.0±0.6 0.010±0.001 2.0±0.1 0.014±0.004 4.0±1.0 0.011± 0.001 
195 1.0±0.2 0.004±0.001 2.0±0.1 0.006±0.001 3.0±1.0 0.015± 0.004 
210 1.0±0.1 0.003±0.001 1.0±0.2 0.005±0.001 2.0±1.0 0.006± 0.001 
225 1.0±0.2 0.002±0.001 1.0±0.2 0.003±0.001 2.0±1.0 0.007± 0.002 
240 1.0±0.1 0.003±0.001 1.0±0.2 0.002±0.001 1.0±1.0 0.004± 0.001 
n.d.= not detected; - = not calculated 
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A preliminary screen was carried out to search for possible metabolites among the new 
analogues studied (INT-2023, INT-2021, INT-2024, T-INT-777, G-INT-777 and T-
INT-1212), the only BA that it is metabolized was INT-2024 that forms its tauro- 
conjugate and it’s chromatographic profile acquire in MRM mode in show below in 
Figure 2.5. 
 
Chromatographic profile of INT-2024 and its metabolite T-INT-2024 in real bile sample 
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Figure 2.5: Example of RIC chromatogram (acquired in MRM mode) obtained from the analysis of bile 
(taken prior to infusion of the synthetic BA INT-2024) diluted with mobile phase 1:10 (v/v). 
 
Tauro- conjugate metabolite of INT-2024 were also estimated even though standard was 
not available to us. Opportune corrective factors, to take into account the different 
responses in ES-MS/MS between free and taurine conjugated species, were estimated 
and applied to the area values obtained from HPLC-MRM dataset chromatograms. In 
the table in the section 2.2.2. there are the parameters of mass spectrometry used for 
follow the taurine metabolite. Finally, calibration curves obtained for the free BA were 
used to estimate taurine conjugated metabolites. 
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Table 2.1.5: Metabolite T-INT-2024 formed to infusion of INT-2024. 
 
Time T-INT-2024 (n=3) Time T-INT-2024 (n=3) 
(min) Conc.±SD Secretion±SD (min) Conc.±SD Secretion±SD 
ID (mmol/l) (µmol/min/kg) IV (mmol/l) (µmol/min/kg) 
75 n.d. - 75 n.d. - 
90 n.d. - 90 n.d. - 
105 0.18±0.09 0.009±0.001 105 2.1±1.7 0.11±0.01 
120 0.4±0.1 0.02±0.01 120 1.6±0.8 0.08±0.02 
135 0.5±0.2 0.02±0.02 135 2.04±0.04 0.10±0.03 
150 0.7±0.6 0.04±0.02 150 0.7±0.2 0.03±0.01 
165 0.6±0.1 0.03±0.01 165 0.2±0.1 0.009±0.002 
180 0.5±0.4 0.022±0.003 180 0.09±0.06 0.0040±0.0005 
195 0.4±0.3 0.01±0.01 195 0.05±0.04 0.00203±0.00008 
210 0.2±0.1 0.007±0.007 210 0.02±0.02 0.0010±0.0003 
225 0.07±0.07 0.003±0.002 225 0.02±0.01 0.00086±0.00007 
240 0.2±0.1 0.008±0.01 240 0.006±0.002 0.0003±0.0002 
 n.d.= not detected; - = not calculated 
 
The concentration and secretion values obtained from rat bile samples collected during 
the femoral infusion (1 hour ranging from 75 to 135 minutes). 
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Figure 2.6: Comparison of INT-2024 and it’s Tauro-INT-2024 (also estimated) derivative mean secretion 
rates vs time in ID and IV experiments at 1 µmol/kg/min for 1 h (n=3). Standard deviations are also 
reported. 
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Figure 2.7: Zoom display of Figure 2.6. 
 
This molecule is mainly secreted as such and only slightly metabolized by the liver. The 
main metabolite is the taurine conjugated specie and it wasn't detected glucuronide 
specie. 
Data regarding other analogues, that have been studied before, and their metabolism and 
conclusions are discussed in sections 4.2. and 4.3. 
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2.3. Conclusions 
 
An improved HPLC-ESI-MS/MS method was developed for the determination of the 
synthetic BA and their major metabolites in bile that meets the general acceptance 
criteria established for bioanalytical studies applied in the pharmaceutical field. 
In the analyzed range the method is accurate, precise, selective and sensitive to enable 
the analysis of molecules of interest in bile samples. 
The method does not require pre analytical extraction and the analyses can be 
performed after a simple dilution step, minimizing the analytical variability and the 
analysis time. 
The use of three internal standards (INT-747, T-INT-747 and G-INT-747) with similar 
structure to the analytes studied in this work and the use of the calibration curves in 
diluted bile made it possible to compensate the effect of suppression of the signal and to 
reduce the problems of inaccuracy. 
The value of LOQ estimated for all analytes is suitable for quantifying the levels of 
concentration of analogues generally found in bile samples collected during the bile 
fistula rat studies. 
 
 
 
 
 
 
 
 
	 59
3. PHYSICO-CHEMICAL PROPERTIES 
 
The new BA analogues were submitted to complete physico-chemical properties 
characterization following protocols previously developed and optimized in our 
laboratory (Hofmann et al. 1984; Roda et al. 1990a; Roda et al. 1982; Roda et al. 1883; 
Roda et al. 1888). These studies were previously applied for the screening of naturally 
occurring BA (Roda et al. 1888; Aldini et al. 1996; Aldini et al. 1996a; Aldini et al. 
1982) and a large series of new BA analogues were developed in R. Pellicciari’s 
laboratory (Pellicciari et al. 1984; Roda et al. 1987; Roda et al. 1988; Roda et al. 1990; 
Roda et al. 1994; Roda et al. 1995). The physico-chemical properties were selected to: 
1) define the behavior in aqueous solutions and in biological fluids 
2) establish their potential toxicity to biological membranes 
3) study their pharmacokinetics, pharmacodynamics, and biodistribution in the different 
biological fluids and organs.  
Analyses of comparative data with natural analogues were also performed and are 
discussed. 
 
3.1. Material and Methods 
 
3.1.1. Chemicals  
 
Natural BA: Chenodeoxycholic acid (CDCA), glycochenodeoxycholic acid (G-CDCA), 
taurochenodeoxycholic acid (T-CDCA), deoxycholic acid (DCA), cholic acid (CA), 
taurocholic acid (T-CA), glycocholic acid (G-CA) were purchased from Sigma (St. 
Louis, MO). Ursodeoxycholic acid (UDCA) was kindly supplied by Giuliani Spa, 
Milan, Italy. All chemical structures are summarized in the Table below.  
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Table 3.1: Natural BA. 
 
Natural BA C3-R1 C7-R2 C12-R3 C23-R4 C6-R5 C16-R6 C23-R7 
CA OH (α) OH (α) OH (α) -CO-OH H H H 
T-CA OH (α) OH (α) OH (α) -CO-NH 
(CH2)2SO3- 
H H H 
G-CA OH (α) OH (α) OH (α) -CO-
NH(CH2)COO- 
H H H 
CDCA OH (α) OH (α) - -CO-OH H H H 
T-CDCA OH (α) OH (α) - -CO-
NH(CH2)2SO3- 
H H H 
G-CDCA OH (α) OH (α) - -CO-
NH(CH2)COO- 
H H H 
DCA OH (α) - OH (α) -CO-OH H H H 
UDCA OH (α) OH (β) - -CO-OH H H H 
 
Synthetic BA: The present work was carried out on the more recent BA analogues 
under study in the Bioanalytical laboratory that include: INT-2021, INT-2023, INT-
2024, T-INT-1212, T-INT-777 and G-INT-777. 
Data regarding INT-747, INT-1075, INT-767, INT-777, INT-1244, INT-1212 and INT-
855 previously developed and fully characterized are also included for a more 
comprehensive interpretation of the structure-activity relationship. All the molecules 
were synthesized, and purified in the laboratory of Prof. Pellicciari (Institute of 
Pharmaceutical Chemistry, University of Perugia, Italy). All the experiments were 
carried out using the sodium salts of the synthesized BA if containing a side chain 
carboxy group. The sodium salts were prepared by adding an equimolar amount of 
NaHCO3 to the aqueous suspension of the free acid, which was heated to 80°C, mixed 
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in an ultrasound bath, and then solubilized in a suitable aqueous solvent for the infusion. 
All chemical structures are summarized in the Table below. 
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Table 3.2: Synthetic BA.  
 
 
 
 
Synthetic BA C3-R1 C7-R2 C12-R3 C23-R4 C6-R5 (α) C16-R6 C23-R7 
INT-747 OH (α) OH (α) - -CO-OH -CH2CH3 H H 
INT-777 OH (α) OH (α) OH (α) -CO-OH -CH2CH3 H -CH3 (S) 
T-INT777 OH (α) OH (α) OH (α) -CO-
NH(CH2)2SO3- 
-CH2CH3 H -CH3 (S) 
G-INT777 OH (α) OH (α) OH (α) -CO-
NH(CH2)COO- 
-CH2CH3 H -CH3(S) 
INT-1075 OH (α) OH (α) OH (α) -CO-OH -CH2CH3 H -CH3(R) 
INT-2021 OH (α) OH (α) OH (α) -CH-OSO3- -CH2CH3 H -CH3 (S) 
INT-2023 OH (α) OH (α) OH (α) -CH2-OSO3- -CH2CH3 H H 
INT-1244 OH (α) OH (α) OH (α) -CH2-SO3- -CH2CH3 H H 
INT-2024 OH (α) OH (α) OH (α) -CO-OH -CH2CH3 OH(β) H 
INT-930 OH (α) OH (α) - -NH-CO-O-
CH2(CH)2-Ph 
-CH2CH3 H H 
INT-1212 OH (α) OH (α) - -CO-OH -CH2CH3 OH(β) H 
T-INT-1212 OH (α) OH (α) - -CO-
NH(CH2)2SO3- 
-CH2CH3 OH(β) H 
INT-855 OH (α) OH (α) - -CO-OH -CH2CH3 H -CH3 (S) 
INT-1213 OH (α) OH (α) - -CH-OSO3- -CH2CH3 H -CH3 (S) 
INT-767 OH (α) OH (α) - -CH2-OSO3- -CH2CH3 H H 
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3.1.2. Critical Micellar Concentration  
 
The critical micellar concentration (CMC) was evaluated by surface tension (ST) 
measurements using a maximum bubble-pressure method (Roda et al. 1983). The 
tensiometer was a Sensadyne 6000 (Chem-Dyne Research Corp., Milwaukee, WI) 
equipped with two glass probes of 0.5 and 4.0 mm in diameter connected to a source of 
compressed air. The bubble frequency was 1 bubble/sec in distilled water at 25°C 
(P=2.7 atm) and the calibration was made with double-distilled water and methanol. 
The ST of the BA solutions, as sodium salts in NaCl 0.15 M, was measured at various 
concentrations ranging from 0.10 to 50 mM. The ST values were plotted against the 
logarithm of the bile salt concentration; the regression lines corresponding to the two 
parts of the curve (monomeric and micellar phases) were calculated using the least 
squares method (Figure 3.1 below), and the intersection of the lines was taken as the 
CMC value. From the ST versus concentration curves, the ST value at the CMC 
(equilibrium between monomeric and micellar phases) was also calculated, giving 
information about the detergency power which is related to the size of the micelles with 
associated ST lowering capacity. The CMC was measured in NaCl 0.15 M to mimic 
physiological conditions (Mysels et al. 1973; Mukerjee et al. 1971). The CMC in water 
would be slightly higher but the values are not relevant for our purposes. 
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Figure 3.1: Surface tension (dyne/cm) plotted against the logarithm of the bile salt concentration (mM) in 
NaCl 0.15 M. 
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3.1.3. Water Solubility 
 
The water solubility was determined only for side chain carboxylated BA INT-777, 
INT-1212, INT-855, INT-747 and INT-2024 since the protonated forms (at a low pH) 
of these compounds are quite insoluble. The sulfate and sulphonate analogues INT-
1213, INT-767, INT-2021, INT-2023 and INT-1244 are highly water soluble at a pH 
range from 0 to 12, such as Tauro-INT-1212, Tauro-INT-777 and Glyco-INT-777. INT-
930 is insoluble at all pH values.  
A small amount (5 mg) of each solid BA was suspended in 5 mL of 0.1 M HCl; INT-
930 was suspended in distilled water. After incubation and gentle mixing for 1 week at 
25°C, the saturated solutions were filtered on a Millipore filter (0.22 µm) and the 
concentration of BA in the solution was measured by high performance liquid 
chromatography-electrospray ionization-mass spectrometry/mass spectrometry 
detection (HPLC-ESI-MS/MS), as reported in detail in Chapter 2, using a Phenyl-Hexyl 
column (150 mm x 2.1 mm internal diameter [id], 5µm) and mobile phases of 
ammonium acetate buffer 15 mM pH 8 and acetonitrile:methanol (3:1 v/v) in ratio 
65:35= aqueous solvent: organic solvent (v/v). The flow rate was 150 µl/min and the 
column was maintained at 45°C. The mass spectrometry acquisition was performed in 
the multiple reaction monitoring mode using the electrospray source in negative 
ionization. Water solubility was expressed as µmol/l. 
 
3.1.4. Octanol/Water Partition Coefficient 
 
The 1-octanol/water partition coefficient (LogP(A-)) was evaluated using a conventional 
shake flask procedure (Roda et al. 1983) for the BA as anion. The experiments were 
carried out using a 0.1 mM bile salt solution buffered at pH 8 with 0.1 M phosphate 
buffer to ensure complete ionization of the BA. The LogP(A-) values refer to the BA in 
the ionized form, not to the protonated species, and the initial concentration of each BA 
was below its own CMC value. The aqueous buffer was previously pre-saturated with 
1-octanol (0.30 mg of 1-octanol are dissolved in 1 liter of water). Five ml of 1-octanol 
pre-saturated with buffer was then added and the samples were left to equilibrate for 4 
days under continuous stirring at room temperature. After centrifugation, the two phases 
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were carefully separated by centrifuge. The BA concentration in the buffer phase, after 
dilution with the mobile phase, was measured by HPLC-ESI-MS/MS,	 as reported in 
detail in Chapter 2, using a Phenyl-Hexyl column (150 mm x 2.1 mm internal diameter 
[id]., 5µm) and mobile phases of ammonium acetate buffer 15 mM pH 8 and 
acetonitrile:methanol (3:1 v/v) in ratio 65:35= aqueous solvent: organic solvent (v/v). 
The flow rate was 150 µl/min and the column was maintained at 45°C. The mass 
spectrometry acquisition was performed in the multiple reaction monitoring (MRM) 
mode using the electrospray source in negative ionization. Octanol/Water partition 
coefficient was expressed as logarithmic ratio of the concentrations. 
LogP(A-) = Log10 ([BA]1-octanol/[BA] water) 
 
3.1.5. Albumin Binding 
 
The extent of albumin binding was evaluated by equilibrium dialysis at a fixed BA 
albumin ratio (Roda et al. 1982; Aldini et al. 1982; Scagnolari et al. 1984). Each BA 
was dissolved at a concentration of 100 µM in 5% bovine serum albumin (BSA fatty 
acid free from Sigma (St. Louis, MO))-saline solution (pH 7.2) and left to stand for 24 
hours at 25°C. Two ml of this solution were dialyzed in cellulose sacs with molecular 
weight cut-off of 12,000 to 14,000 Dalton (Spectra/Por, Spectrum Medicai lndustries 
lnc., Los Angeles, CA) against 25 ml of saline solution. The system was equilibrated by 
gently shaking for 72 hours at 25°C. The BA concentrations of the dialyzed solution 
(corresponding to the free unbound fraction) and of the starting solution were 
determined with HPLC-ESI-MS/MS under the same conditions as the previous analysis. 
The percentage of albumin binding was calculated from the initial BA concentration 
and from the unbound concentration in the dialyzed fraction.  
 
3.1.6. Critical micellar pH 
 
The critical micellar pH represents the pH at which a solid BA dissolves in a micellar 
phase. This is relevant to simulate the dissolution of the drug from the gastric content to 
the duodenal juice where the BA concentration is higher than the CMC. 
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This pH value is defined as critical micellar pH (CMpH) which, as well as 
experimentally, can be calculated from the pKa, the CMC and the solubility of the 
protonated form of that particular BA according to the equation: 
 
CMpH= pKa + log (CMC/Ws) 
 
3.2. Results and Discussion 
 
3.2.1. Critical Micellar Concentration  
 
All the studied BA analogues present amphipatic properties and behave like detergent-
like natural occurring BA. All the data were obtained using the same analytical and 
physico-chemical methodologies to facilitate the comparative evaluation of the recent 
data obtained on INT-2024, INT-2021, INT-2023, INT-2024, T-INT-1212, T-INT-777 
and G-INT-777 with those obtained in the previous studied analogues which include: 
INT-747, INT-1075, INT-767, INT-777, INT-1244, INT-1212 and INT-855 a more 
large series of other analogues and natural BA. 
 
Synthetic analogues of 6-Ethyl-CDCA: 
It has been previously reported that the relatively low CMC value of INT-747 (2.9 mM) 
quite similar to that of CDCA (3.0 mM) is related to the topographic distribution of the 
ethyl and hydroxyl groups: the ethyl group in position 6 is oriented in the β face, the 
back of the steroid, contributing to increase the lipophilicity of the surface of this 
moiety and therefore the tendency to form micelles via back to back interaction. 
Moreover the two 3α and 7α hydroxyl are oriented on the opposite face facilitating the 
growth of micelles fro dimer to tetramer and multiper via hydrogen bonding interaction. 
 
Synthetic sulphonate and sulphate analogue of 6-Ethyl-CDCA: 
INT-767 (1.3 mM) presents the lowest CMC of the studied analogues as a result of the 
ethyl group in position 6 and sulphate head in the side chain. The peculiar properties of 
the sulphate group gave INT-767 (synthetic derivative of CDCA) anionic surfactant like 
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properties (like sodium dodecyl sulphate) as a result of a negative charged head in the 
tail with a lipophilic steroid moiety. INT-1213 has not yet been admitted to this study 
 
Synthetic carboxylated analogues of 6-Ethy-CA: 
INT-777 (2.0 mM) presented a lower CMC with respect to the natural CA analogues (9 
mM) again as a results of the presence of the Ethyl group. However, it had a moderate 
detergency power as documented by the high surface tension values at the CMC higher 
in respect to CA or other analogues. The results suggest that this molecule is able to 
form micelles even at low concentrations but the micelles have a low aggregation 
number and size and are therefore characterized by a low detergency power (low 
detergency means low toxicity to membranes or cells). 
 
Synthetic sulphonates and sulphate analogues of 6Ethyl-CA: 
INT-1244 presented a CMC of 2.8 mM this value is within the range of a medium-high 
detergent molecule. The CMC was slightly higher than INT-767 (1.3 mM), suggesting 
that an additional hydroxyl group balances the presence of the 6-ethyl group. The 
behavior of the ST versus concentration suggests the formation of relatively large 
aggregates with consistent detergency. The CMC values suggest that this molecule is 
potentially less toxic than other CDCA analogues with a lower CMC, e.g. INT-767.  
INT-2021 and INT-2023 (ethyl group in position 6 and sulphate 23 in the side chain) 
presenting a behavior of low detergency even if the 23α-methyl in INT-2021 increases 
the CMC up to 5.6 mM compared to INT-2023 (2.6 mM) that has only the ethyl group 
in six position as a difference. 
 
Synthetic carboxylates analogues of CDCA and CA containing a 16β- hydroxyl: 
INT-1212 and INT-2024 presented relatively high CMC values (respectively 5.9 and 
6.3 mM) with a low ST lowering capacity. This indicates that these compounds are 
moderate detergents and the micelles have a very low aggregation number. The 
presence of a hydroxyl group in the 16β position reduces the hydrophobic area 
responsible for back to back interactions and gives the molecule a low potential toxicity 
when accumulated in a given biological fluid or organ. 
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Taurine and glycine conjugated analogues: 
The detergency of taurine / glycine conjugates of INT-777 and INT-1212 is higher, i.e. 
the CMC is lower than the corresponding free form as a result of increased side chain 
length. The CMC data are similar to natural occurring taurine/glycine conjugated BA 
such as TCA, GCA and TCDCA. 
 
In general, BA with a CMC<1 mM and a low ST tension value at the CMC in the order 
of 40 dyne/cm are detergents and potentially toxic if they accumulate in a target organ 
at a concentration higher than the CMC. 
lf the ST tension is > 45-50 dyne/cm, the BA forms aggregates at a low concentration 
but these micelles are small and therefore with less detergent power.  
A CMC < 1mM and ST < 40 dyne/cm are criteria of exclusion or to admit the molecule 
to additional studies regarding their potential toxicity (membrane toxicity, cytotoxicity).  
BA with a CMC >20-30 mM behaves more likely an organic anion and not as an 
anphipatic molecule with different PK and biological effects. 
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All data of CMC are summarized in the Table 3.3 below (in mM ± SD). 
 
BA CMC(b) 0,15 M Na+ (mM) BA CMC(b) 0,15 M Na+ (mM) 
CDCA 3.2 ± 0.2 CA 9.0 ± 0.2 
INT-747 2.9 ± 0.1 INT-777 2.0 ± 0.3 
INT-767 1.3 ± 0.1 T-CA 4.0 ± 0.3 
INT-1213 Not available T-INT-777 1.4 ± 0.2 
INT-855 - G-CA 8.0 ± 0.1 
INT-930 Not determined G-INT-777 1.3 ± 0.3 
INT-1212 5.9 ± 0.2 INT-1244 2.8 ± 0.1 
T- INT-1212 2.7 ± 0.2 INT-2021 5.6 ± 0.2 
T-CDCA 3.0 ± 0.1 INT-2023 4.1 ± 0.2 
G-CDCA 2.0 ± 0.3 INT-2024 6.5 ± 0.4 
DCA 3.0 ± 0.2 UDCA 10.0 ± 0.1 
BA STCMC(c) Dyne/cm BA STCMC(c) Dyne/cm 
CDCA 45.5 CA 49.0 
INT-747 48.8 INT-777 50.1 
INT-767 47.9 T-CA 51 
INT- 1213 Not available T-INT-777 47.8 
INT-855 - G-CA 48.8 
INT-930 Not determined G-INT-777 43.8 
INT-1212 52.4 INT-1244 43.4 
T- INT-1212 43.6 INT-2021 38.3 
T-CDCA 47 INT-2023 42.6 
G-CDCA 45.2 INT-2024 43.2 
DCA 50.2 UDCA 50.5 
 b CMC: Critical Micellar Concentration determined in 0,15 M NaCl water solution. 
 c STCMC: Surface Tension at CMC in 0,15 M NaCl water solution. 
 
3.2.2. Water Solubility 
 
The water solubility was measured for the insoluble protonated species of the 
carboxylated BA at pH 1 to ensure complete protonation of the carboxyl group.  
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Synthetic analogues of 6-Ethyl-CDCA: 
All the new synthetic analogues studied present low solubility when protonated, as was 
observed in the previous studies for INT747, INT855, INT1212 and INT1244. 
The water solubility of INT-747 and INT-855 was, respectively, 9 and 15 µM, slightly 
lower than CDCA (32 µM), and comparable with that of UDCA (7 µM). The water 
solubility of INT-930 was very low as a result of the side chain modification and the 
lack of charged groups in the molecule. INT-930 remained practically insoluble at all 
the pH values since no ionizable groups are present in the molecule. 
 
Synthetic carboxylated analogues of 6-Ethy-CA: 
The water solubility of INT-777 was 99 µM which is lower compared to the CA (273 
µM). The presence of a C23-Methyl group and C6-Ethyl group in the compound INT-
777 decreases the water solubility. Moreover, other factors are involved in determining 
the solubility, including the stability of the solid state as documented by differences in 
the melting points. 
 
Synthetic sulphonate , sulphate, taurine and glycine conjugated analogues of 6-Ethyl-
CDCA and 6Ethyl-CA : 
The sulphate and sulphonate compounds, INT-767, INT-1244, INT-2021, INT-2023, 
INT-1213 and taurine / glycine conjugates which are fully ionized even at low pH and 
in physiological conditions, were highly soluble in all biological fluids. 
 
Synthetic carboxylate analogues of CDCA and CA containing a 16β- hydroxyl: 
INT-1212 is a synthetic analogue containing C6-Ethyl and two hydroxyl groups in 
position 3-α and 16-β and INT-2024 a similar structure with one more hydroxyl group 
in position 12-α.  
The water solubility of INT-1212 and INT-2024 were, respectively, 120, and 290 µM 
which is higher than the corresponding trihydroxy BA and comparable with that of CA 
(273 µM). INT-2024 exhibited the highest solubility, perhaps due to the presence of the 
hydroxyl group in 12-α. The different position of the hydroxyl (16β-position) in the 
compound INT-1212 also slightly reduced the solubility when compared to the 
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conventional 3α,7α,12α-trihydroxy BA (CA). Moreover these differences are better 
explained by the solid state properties.  
 
Glycine conjugated analogues: 
The natural BA conjugated with glycine (G-CA and G-CDCA) show different solubility 
values in comparison to the corresponding unconjugated BA; the Ws of CA is 273 mM 
while GCA 32 mM on the contrary CDCA 7 mM present lower value in respect to 
GCDCA (32 mM).  
The relationship structure-solubility is mainly affected by the stability of the solids state 
and therefore more detailed studies on solid state should be performed.  
The analogue conjugate with glycine (G-INT-777) shows a higher solubility compared 
to INT777, in fact the Ws for the INT-777 increased from 99 mM to 1700 mM for G-
INT-777. 
All data of Ws are reported in the Table 3.4 below (in µM ± SD). 
 
BA Ws (a) (µM) BA Ws (a) (µM)
CDCA 32 ± 4 CA 273 ± 10 
INT-747 9 ± 1 INT-777 99 ± 7 
INT-767 hs  T-CA hs 
INT -1213 hs T-INT-777 hs 
INT-855 15 ± 3 GCA 32 ± 3 
INT-930 <0.02 G-INT-777 1700 ± 20 
INT-1212 120 ± 9 INT 1244 hs 
T- INT-1212 hs INT-2021 hs 
T-CDCA hs INT-2023 hs 
G-CDCA 7 ± 1 INT-2024 290 ± 15 
DCA 28 ± 2 UDCA 7 ± 1 
a Ws: water solubility refers to BA as protonated species 
hs: high solubility 
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3.2.3. Octanol/Water Partition Coefficient 
 
The 1-octanol/water partition coefficient was measured for the ionized species to 
facilitate the comparison between the carboxyl and sulphate BA since the latter do not 
protonate even at very low pH values. 
 
Synthetic analogues of 6-Ethyl-CDCA: 
INT-747 and INT-855 (respectively 2.5 and 2.9) present a slightly higher lipophilicity 
with respect to other dihydroxy BA such as UDCA and CDCA. The increased 
lipophilicity is the result of the introduction of an ethyl group in position 6. The increase 
is even higher for INT-855 due to the presence of a C23-Methyl group. The tendency of 
these analogues to distribute in a lipid domain is therefore higher.  
The logP of carbamate analogue INT-930 (4.0) was much higher than all the 
compounds, indicating that this compound accumulates preferentially in lipid domains. 
This is due to the side chain modification with the introduction of a relatively large 
moiety and without any charged group. 
 
Synthetic sulphonate and sulphate analogues of 6-Ethyl-CDCA: 
The INT-767 shows a logP of 2.0, a value slightly lower than INT-747 and natural 
CDCA and UDCA analogues, and this accounts for the contribution of the sulphate 
group and side chain. INT-767 has a tendency to accumulate in a lipid domain like INT 
747, DCA, INT-930 and INT-855.  
The sulphate analogue INT-1213 (2.3) shows a lipophilicity higher than INT-767, due 
to the presence of the methyl group in C23, but was still in a range of expected values 
according to the chemical structure. 
 
Synthetic carboxylated analogues of 6-Ethy-CA: 
The carboxylated analogue INT-777, with three hydroxyl groups in positions 3, 7 
and 12 , and a C-23 Methyl shows a slightly higher lipophilicity with respect to the 
natural analogue CA. This is the result of the presence of an ethyl group in position C-6 
and a methyl group in position C-23. 
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Synthetic sulphonates and sulphate analogues of 6Ethyl-CA: 
The low Log P values of sulphonate and sulphate analogues of 6Ethyl-CA such as INT-
1244 ,INT-2023,, and INT-2021 show a lower lipophilicity than the similar compound 
analogues of 6Ethyl-CA like INT-767 as a result of the presence of one additional 
hydroxyl group (three α-OH groups in 3, 7 and 12) in the steroid rings. 
 
Synthetic carboxylates analogues of CDCA and CA containing a 16β- hydroxyl: 
The LogP of the carboxylated analogue INT-1212 (1.6), with three hydroxyl groups in 
positions 3, 7 and 16 , indicates a slightly higher lipophilicity with respect to the 
natural analogue CA due to the presence of the ethyl in position C-6. This difference is 
likely due to the uncommon position of the 16 hydroxyl group, considering that 
position 12 does not appear to play a major role in the detergency properties. 
The carboxylated analogue which presents the highest hydrophilicity was INT-2024 (-
0.05) which is a derivative of cholic but with an extra hydroxyl group in 16β . 
 
Taurine and glycine conjugated analogues: 
T-CDCA, T-INT-1212, T-INT-777 and G-INT-777 present LogP values of, 
respectively, 0.9, 0.3, -0.2 and 0.3. These values suggest that the taurine and glycine 
conjugated analogues preferentially stay in a water domain and the modification in the 
structure does not change their hydrophilicity. 
 
In general, BA with a LogP <1 are hydrophilic and poorly absorbed by the intestine via 
a passive mechanism. Glycine and Taurine conjugated BA, despite having a low 
LogP(A-), are absorbed in the ileum not passively but via an active mechanism 
recognized by specific transporters independently from their physico-chemical 
properties.  
Novel BA with uncommon side chain structure and a logP<1 are nor absorbed paasively 
and eventually must be subjected to an additional in vivo study to evaluate if they can 
be absorbed by an active mechanism. BA with a LogP(A-) >3 are highly lipophilic and 
thus potentially toxic even at low concentrations since they can accumulate in a lipid 
domain within target tissues and cells. All data of LogP(A-)A- are summarized in the  
Table 3.5 below ((LogP = Log10 ([BA]1-octanol/[BA]water) ± SD). 
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BA LogPA-(d) BA LogPA-(d) 
CDCA 2.2 ± 0.2 CA 1.1 ± 0.2 
INT747 2.5 ± 0.3 INT-777 1.4 ± 0.2 
IN-T767 2.0 ± 0.1 T-CA -0.5 ± 0.1 
INT-1213 2.3 ± 0.2 T-INT-777 -0.2 ± 0.1 
INT-855 2.9 ± 0.2 G-CA -0.4 ± 0.1 
INT-930 4.0 ± 0.3 G-INT-777 0.3 ± 0.1 
INT-1212 1.6 ± 0.1 INT-1244 0.7 ± 0.1 
T- INT-1212 0.3 ± 0.1 INT-2021 0.7 ± 0.1 
T-CDCA 0.9 ± 0.1 INT-2023 0.6 ± 0.1 
G-CDCA 0.4 ± 0.1 INT-2024 -0.05 ± 0.1
DCA 2.6 ± 0.2 UDCA 2.2 ± 0.1 
d LogPA-: 1-octanol-water partition coefficient of the studied BA as ionized species. 
 
3.2.4. Albumin Binding  
 
Synthetic analogues of 6-Ethyl-CDCA: 
INT-747 (96%) presents a strong interaction with albumin quite similar to natural 
dihydroxy BA like CDCA and UDCA, suggesting similar kinetics in the hepatic uptake. 
INT-747 presents a relatively low unbound fraction and we expected that when 
absorbed by the intestine the compound will reach the lived via portal vein and a 
relatively high quantity will reach serum concentration via spill over as a result of a 
relatively low first pass clearance; however its behavior is similar to natural 
unconjugated analogs. 
 
Synthetic sulphonate and sulphate analogues of 6-Ethyl-CDCA: 
The sulphate analogue INT-767 present a strong interaction with albumin quite similar 
to natural dihydroxy BA like CDCA and UDCA, suggesting similar kinetics in the 
hepatic uptake. INT-767 presents a low unbound fraction and its serum concentration is 
therefore higher as a result of a relatively low first pass clearance, and its behavior is 
similar to natural analogs. 
The percent albumin binding of INT-1213 (97%) is slightly higher than that of INT-767 
(85%) as a result of the addition of the methyl group in position C-23. 
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Synthetic carboxylated analogues of 6-Ethy-CA: 
The percent albumin binding of INT-777 (62%) was comparable than CA (70%). 
 
Synthetic sulphonates and sulphate analogues of 6Ethyl-CA: 
The percent albumin binding of INT-1244, INT-2021, and INT-2023 sulphonate 
analogue) were similar to natural taurine conjugated BA analogues. 
 
Synthetic carboxylates analogues of CDCA and CA containing a 16β- hydroxyl: 
The percent albumin binding of INT-2024 and INT-1212 don’t showed problem as the 
results obtained are comparable with the natural BA. 
 
Taurine and glycine conjugated analogues: 
For all taurine conjugate analogues studied, such as T-INT-777 and T-INT1212, the 
albumin binding is approximately 80% similarly to natural occurring BA . Similarly for 
G-INT-777.  
All of these compounds presented an albumin binding compatible with a relatively fast 
hepatic uptake, similar to naturally occurring BA.  
The structural modification in the sulphate and sulphonate analogues do not modify the 
albumin binding and therefore we expected that these compounds exhibit a PK similar 
to common BA. All data of albumin binding (%) are summarized in the Table 3.6 below 
(in % ± SD). 
 
BA Albumin binding (%) BA Albumin binding (%) 
CDCA 96 ± 2 CA 70 ± 1 
INT-747 96 ± 3 INT-777 62 ± 2 
INT-767 85 ± 2 T-CA 82 ± 3 
INT-1213 97 ± 1 T-INT-777 81 ± 1 
INT-855 97 ± 1 G-CA 65 ± 1 
INT-930 99 ± 2 G-INT-777 71 ± 2 
INT-1212 83 ± 3 INT-1244 81 ± 1 
T- INT-1212 86 ± 1 INT-2021 74 ± 2 
T-CDCA 70 ± 2 INT-2023 71 ± 2 
G-CDCA 85 ± 1 INT-2024 47 ± 3 
DCA 95 ± 1 UDCA 94 ± 2 
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3.2.5. Critical micellar pH 
 
The CMpH value of INT-747 is similar to that of CDCA and lower than UDCA. 
According to this value, INT-747 does not present problems of intestinal solubility and 
requires a pH of 7.6 which is physiological to go in solution in a micellar phase. For 
example, UDCA with a CMpH of 8.4 requires a higher alkalinization of the duodenal 
content and is solubilized in a micellar phase only in the post-prandial phase. 
Analogues with three or four hydroxyl groups like INT-777, INT-2024 and INT-1212 
have similar values to the CA so do not present problems of intestinal solubility. 
INT-767, INT-1213, INT-2021, INT-2023 and taurine conjugated BA having a sulphate 
group do not present these problems since they are always soluble in the physiological 
pH from 2 to 9 as the pKa is very low and the compound is not protonated to form 
insoluble molecule.  
The data show that, when administered in their acid form, the carboxylated analogues 
INT-2024, INT-855, INT-747, INT-777 and INT-1212 remain insoluble in the gastric 
content at a low pH and go into solution to form the salt (anion) once excreted into the 
duodenum due to the higher pH of the pancreatic and duodenal fluids. In the bile, they 
remain in solution, eventually forming micelles with other lipids. 
To summarize, we avoid compounds characterized by a very low solubility in 
protonated form and with a high CMC if their pKa is 5. This is common for natural 
unconjugated BA while for sulphate or sulphonate analogues having a very low pKa 
and a high solubility in a wide range of pH, this is not a problem. 
All The CMpH values are summarized in the table 3.7 below. 
 
BA CMpH BA CMpH BA CMpH 
CDCA 7 CA 6.5 INT-2023 - 
INT-747 7.2 INT-777 6.1 INT-2024 6.3 
INT-767 - T-CA - UDCA 8.4 
INT-1213 - T-INT-777 - T-CDCA - 
INT-855 - G-CA 6.3 G-CDCA 6.4 
INT-930 - G-INT-777 3.9 DCA 7.3 
INT-1212 6.7 INT-1244 -   
T- INT-1212 - INT-2021 -   
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3.3. Conclusions 
 
The previous extensive study of many naturally occurring BA and structurally modified 
BA allows us to understand that minor modifications in the BA molecule are able to 
modify their physico-chemical properties and on turn to target the molecule to a given 
organ and therefore playing a role in their pharmacokinetics, metabolism and activity. 
For example, modifications in side chain structure (length, other modifications) 
determine the detergent-like properties while modifications in number, position, 
orientation of -OH and other groups play a role in the hydrophobic/hydrophilic balance. 
We have selected the physico-chemical properties that properly define BA behaviour in 
aqueous solutions and in biological fluids and are appropriate to predict: 
a) Water solubility (protonated specie): Problems of formulation and solubility in the 
intestinal content (low pH). 
b) CMC (critical micellar concentration): Toxicity, membrane structure modification, 
surface tension lowering capacity, interaction and aggregation with lipids, proteins. 
c) Critical micellar pH: Solubility at different pH (gastric juice, intestinal content)  
d) Lipophilicity (LogP O/W partition coefficient): Predicts the efficiency of intestinal 
absorption, body fluid distribution and toxicity. 
e) Albumin binding: related to the blood transport and hepatic uptake. 
The Table 3.8 below summarizes the functions of BA, the organic sector and important 
physico-chemical properties. 
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Table 3.8: Physico-chemical properties of the studied analogues and naturally occurring 
BA. 
 
BA 
Ws (a) 
(µM) 
CMC(b) 0.15 
M Na+ (mM) 
STCMC 
Dyne/cm 
CMpH LogPA-(d) pKa 
Albumin 
binding (%) 
CDCA 32 3 45.5 7 2.2 5 96 
GCDCA 7 2 45.2 6.4 0.4 3.9 85 
TCDCA hs 3 47 - 0.9 <1 70 
DCA 28 3 50.2 7.3 2.6 5 95 
UDCA 7 10 50.5 8.2 2.2 5 94 
CA 273 9 49 6.5 1.1* 5 70 
TCA hs 4 51 - -0.5 <1 82 
GCA 32 8 48.8 6.3 -0.4 3.9 65 
INT-767 hs 1.3 47.9 - 2.0 <1 85 
INT-747 9 2.9 48.8 7.2 2.5 5 96 
INT-1244 hs 2.8 43.4 - 0.7 <1 81 
INT-1213 hs Not available Not available - 2.3 5 97 
INT-1212 120 5.9 52.4 6.7 1.6 <1 83 
T- INT-1212 hs 2.7 43.6 - 0.3 <1 86 
INT-855 15 - - - 2.9 5 97 
INT-930 <0.02 
Not 
determined 
Not 
determined 
- 4 
<1 
99 
INT-2021 hs 5.6 38.3 - 0.7 - 74 
INT-2023 hs 2.6 42.6 - 0.6 <1 71 
INT-2024 290 6.3 43.2 6.3 -0.05 5 47 
INT777 99 2 50.1 6.1 1.4 5 62 
T-INT-777 hs 1.4 47.8 - -0.2 <1 81 
G-INT-777 1700 1.3 43.8 3.9 0.3 3.9 71 
 
a Ws: water solubility refers to BA as protonated species  
b CMC: Critical Micellar Concentration determined in 0,15 M NaCl water solution. 
c STCMC: Surface Tension at CMC in 0,15 M NaCl water solution. 
d LogPA-: 1-octanol-water partition coefficient of the studied BA as ionized species. 
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Summary of the chemical-physical parameters of BA in relation to the values obtained: 
 
CMC 
Transport and lipid 
solubilization (Bile) 
Intestinal absorption 
(Duodenal Juice) 
↓ Hydrophobic area (β face) ↑CMC (CDCA<CA<UDCA) 
↓Side chain length↑CMC 
↑Side chain length ↓ CMC 
Detergency of Taurine/Glycine BA (low CMC) > Free BA 
Ws 
Hepatic uptake (Serum) 
 
Intestinal absorption 
(Duodenal Juice) 
Sulphonated/Sulphates/Taurine-BA soluble at all 
physiological pH 
Glycine BA soluble at pH > 5.5 
Free BA soluble at pH > 7.0 
LogP 
Intestinal absorption 
(Duodenal Juice) 
 
Hepatic uptake (Serum) 
 
Hepatic transport (Liver) 
The LogP correlated with the rate and extent of ileal passive 
absorption : 
Taurine BA LogP ≤ 0 impaired passive intestinal absorption. 
Glycine BA LogP>0 compatible with a passive intestinal 
absorption. 
Free BA LogP > 1.0 passive intestinal absorption. 
BA LogP > 3.0 toxicity index 
Albumin binding 
Hepatic uptake (Serum) 
The affinity of the BA for albumin is reduced by an increase 
in the polarity of the steroid ring. 3-OH BA<2-OH BA and 
Turo/Glyco BA < Free BA. 
More BA will bind to albumin more the hepatic uptake will 
be high. 
More the affinity of the BA for albumin is high, more the 
hepatic uptake will be high. 
CMpH 
Intestinal absorption 
(Duodenal Juice)  
Required CMpH < 8.5 
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4. PHARMACOKINETICS AND METABOLISM OF THE 
BA ANALOGUES: IV and ID single –dose administration to 
bile-fistula rat model.  
 
This study has been performed following the protocol and the animal model used in 
previous works for the study of a large amount of natural occurring BA and related 
synthetic analogues which allow us to define the relationship between physico-chemical 
properties and pharmacokinetics and metabolism in the rat (Aldini et al. 1996, 1996a, 
1992a, 1992, 1990, 1989, 1982, 1981; Roda et al. 1993, 1988a, 1987, 1985; Montagnani 
et al. 1996). The role of side chain length and structure and the number, position and 
orientation of hydroxyls in determining the detergency, lipophilicity and in turn their 
intestinal absorption, hepatic uptake and metabolism has been previously well 
established and this facilitates the design of new organ specific analogues , with a PK 
adequate for their pharmacological activity (Pellicciari et al. 2009, 1989, 1985, 1984; 
Roda et al. 1995, 1995, 1994, 1990, 1989, 1988a, 1988, 1987; Clerici et al. 1992). 
The first studied analogues INT-747 (EC50= 0.1 µM determined by Alpha Screening 
FXR test), a potent FXR agonist now in phase 3 clinical trial in man, is an analogue of 
CDCA having an Ethyl group in six position. Thank to this modification the interaction 
with the FXR receptor was more potent than CDCA with a EC50= 13 µM (Rizzo et al. 
2010). 
This structural modification does not play a role only in the receptor fitting but also in 
the BA physico-chemical properties and metabolism as previously described for other 6 
substituted BA such as 6-Methyl-UDCA (Roda et al. 1995, 1995, 1994) ; the presence 
of a 6-Ethyl group sterically hinders the 7-dehydroxylation by dehydroxylases enzyme 
present in the intestinal bacterial, thus preventing the formation of potentially more 
toxic monohydroxy analogues. The 6-Ethyl group is shared by all the studied analogues 
since is important in determining the potency as agonist for FXR and also for TGR5 
receptor , as more recently reported.  
Modification in the side chain are also very important and profoundly modify the 
physico-chemical properties and the related PK as previously reported. 
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The presence of a 23-Methyl in the side chain prevents the first step in the conjugation 
with glycine and taurine in the liver i.e. the carboxyl CoA activation process by steric 
hindrance and in turn a Tauro-23-Methyl conjugate is highly stable toward cholyglycine 
hydrolases present in the intestinal bacteria again due to the lack of substrate specificity 
for these enzymes. 
The role of conjugation with glycine and taurine is a metabolic prerequisite to reduce 
the lipophilicity of a BA to a critical value accounting for the possibility to be secreted 
into bile and conserved in the enterohepatic circulation. 
If the amidation is prevented, a lipophilic BA could be excreted by the liver via 
formation of polar glucuronide not anymore preserved in the enterohepatic circulation. 
To evaluate the PK and metabolism of synthetic BA, these BA analogues were 
administered both intra-duodenally (id) and intravenously(iv) at a dose of 1 
μmol/min/kg (1 hour infusion) and the choleretic effect, biliary secretions rate and 
hepatic metabolism were evaluated in bile fistula rat model following the protocols 
previously used for natural BA and other synthetic analogues. These studies have been 
performed by Dott. Aldini group at the University Hospital S.Orsola, Bologna. 
The quantitative determination of the compound in bile and its main metabolites after id 
administration allows to define the rate and extent of intestinal adsorption while after 
intravenous (iv) the hepatic uptake , metabolism can be defined. The two models are 
summarized in Figure 4.1 below. 
 
Id
Infusion
Iv
Infusion
Bile collection
Bile collection
 
Figure 4.1: Bile fistula rat model after duodenal (id) and femoral (iv) administration 
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According to previously defined the administered compound will be secreted into bile 
unmodified and efficiently only if hydrophilic with a LogP < 1 while, if lipophilic, it 
will be metabolized by the liver such as tauro and glyco conjugates.  
Although the bile fistula model is the classical accepted model for the in vivo study of 
the intestinal absorption, the hepatic uptake , transport and biliary secretion are also 
involved and can some how influence the absorption kinetics. Anyway the BA will be 
absorbed passively along the entire intestinal tract if the molecules are relatively 
lipophilic (LogP(A-)) similary to unconjugated natural analogues such as CDCA. An 
active carrier-mediated mechanism in the terminal ileum operates only for the 
corresponding taurine and glycine conjugates if they still have a structure similar to 
natural analogues such as TCDCA.  
 
4.1. Material and methods  
 
4.1.1. Chemicals  
 
Natural BA:  
Chenodeoxycholic acid (CDCA) and taurochenodeoxycholic acid (T-CDCA) were 
purchased from Sigma (St. Louis, MO).  
All chemical structures are summarized in Table 3.1 in chapter 3. 
 
Synthetic BA:  
The present work has been carried out on the more recent BA analogues under study in 
the Bioanalytical laboratory that include: INT-2021, INT-2023, INT-2024, T-INT-1212, 
T-INT-777 and G-INT-777. 
Data regarding INT-747, INT-767, INT-777, INT-1244, INT-1212, INT-855 and INT-
1057 previously developed and fully characterized are also included for a more 
comprehensive interpretation of the structure-activity relationship. 
All the molecules have been synthesized, purified in the laboratory of Prof. Pellicciari 
(Institute of Pharmaceutical Chemistry, University of Perugia, Italy). All the 
experiments were carried out using the sodium salts of the synthesized BA if containing 
a side chain carboxyl group. The sodium salts were prepared by adding an equimolar 
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amount of NaHCO3 to the aqueous suspension of the free acid, which was heated to 
80°C, mixed in an ultrasound bath, and then solubilized in a suitable aqueous solvent 
for the infusion. All chemical structures are summarized in Table 3.2 in chapter 3. 
 
4.1.2. Duodenal infusion  
 
The protocol of the animal model and the experimental studies have been carried out by 
Dott.R. Aldini group, as a part of the collaboration with the Bioanalytical Laboratory. 
All the analogues were administered by intraduodenal infusion via a non flexible 
stainless steel curved button-ended needle (18G) at a dose of 1 μmol/min/kg (1 hour 
infusion) to male Wistars-Han rats (body weight 240 ± 10 g) .  
Bile was collected by a drainage via a siliconated catheter implanted in the common bile 
duct in preweighted tubes and blood was also collected from the femoral vein at 30 m in 
time intervals. Duodenal infusion started after 75 minutes steady state and continued for 
60 minutes. Bile samples were collected every 15 minutes for 3 hours. Samples were 
stored at -20°C until analysis. The bile samples were weighed and the bile secretion rate 
was calculated and expressed as a µL/min/Kg b.w. Biliary secretion of analogues and 
their metabolites were expressed as µmoles/min/Kg b.w.  
In addition, 3 control rats were treated with saline solution under the same conditions 
for time and sampling (duodenal control rats) and additional 3 rats were treated with 
CDCA and TCDCA under the same conditions for time and sampling.  
 
4.1.3. Intravenous infusion 
 
The analogues were administered at a dose of 1 μmol/min/kg (1 hour infusion) in a 
saline solution containing BSA 3% (w/v) to a group of 3 male Wistar-Han rats (body 
weights 240 ±10 g) via femoral vein cannulation (iv).  
Femoral infusion started after 75 minutes steady-state and continued for 60 minutes. 
Bile samples were collected every 15 minutes for 3 hours. The bile samples were 
weighed and the bile secretion rate was calculated and expressed as a µL/min/Kg b.w. 
Biliary secretion of analogues and their metabolites was expressed as µmoles/min/Kg 
b.w. 
	 83
In addition, 3 rats were treated with saline solution with 3% (w/v)BSA under the same 
conditions for times and sampling (femoral control rats) and other 3 rats were treated 
with CDCA and TCDCA under the same conditions for time and sampling . 
 
4.2. Results and discussion 
 
4.2.1. Choleretic effect after id and iv administration 
 
The choleretic effect of the administration of analogues was evaluated in comparison to 
untreated bile fistula rats by measuring the amount of bile secreted and the effect of id 
and iv administration was compared.  
As a further controls the effect was also compared with that produced by the 
administration of CDCA and TCDCA at equimolar dose. 
The mean (n=3) bile maximum secretion rates (µl/min/Kg ± SD) after iv and id 
administration of analogues, CDCA, TCDCA and untreated rats are reported in the 
Table 4.1 below.  
Data obtained in previous works on INT-747, INT-767, INT-777, INT-1244, INT-1212, 
INT-855 and INT-1075 have been reported in order to allow a comparison with similar 
new analogues as INT-2021, INT-2023, INT-2024, T-INT-1212, T-INT-777 and G-
INT-777 have been included in the table for comparative evaluation.  
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Maximum secretion 
Bile flow (µl/min/Kg) BA administered 
I.V. I.D. 
Natural BA and control rat 
CDCA 63 ± 3 65 ± 5 
CONTROL 50 ± 1 50 ± 3 
Synthetic analogues of 6-Ethyl-CDCA 
INT-747* 83 ± 2 70 ± 2 
INT-855* 60 ± 4 61 ± 6 
Synthetic sulphonate and sulphate analogue of 6-Ethyl-CDCA 
INT-767* 65 ± 2 58 ± 3 
Synthetic carboxylated analogues of 6-Ethy-CA 
INT-777* 130 ± 2 115 ± 1 
INT-1075* 85 ± 7 - 
Synthetic sulphonates and sulphate analogues of 6Ethyl-CA 
INT-1244* 65 ± 6 87 ± 1 
INT-2021 73 ± 1 40 ± 2 
INT-2023 63 ± 3 53 ± 4 
Synthetic carboxylates analogues of containing a 16β- hydroxyl 
INT-1212* 60 ± 2 57 ± 1 
INT-2024 52 ± 2 47 ± 2 
Taurine and glycine conjugated analogues 
T-INT-777 60 ± 5 57 ± 4 
T-INT-1212 56 ± 1 40 ± 2 
G-INT-777 64 ± 4 60 ± 3 
T-CDCA 41 ± 2 44 ± 2 
    (*)Data obtained in previous works 
 
The effect on bile flow due to the duodenal administration of the reference compound 
CDCA is reported. The infusion of CDCA, in comparison to the control rat, slightly 
increased the bile flow during id and iv administration. 
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Synthetic analogues of 6-Ethyl-CDCA: 
INT-747 and INT-855 have been previously studied. 
After iv administration INT-747 increases the bile flow reaching maximum levels of 
approximately 80 μl/min/Kg. The induced bile flow after id administration is slightly 
lower than iv administration  
After id and iv infusion of INT-855 do not modify the bile flow in respect to control 
animal. 
None of them is cholestatic at the administered dose. 
 
Synthetic sulphonate and sulphate analogue of 6-Ethyl-CDCA: 
A series of side sulphate and sulphonate analogues of CDCA have been previously 
studied including: 
INT-767 analogue with a side chain sulphate ester head. 
INT-1213 analogue with a side chain sulphate ester head and a C23-Methyl group (no 
further developed).  
The id and iv infusion of INT-767 slightly increases the bile flow rate and the effect is 
slightly higher after iv infusion. 
None of them is cholestatic at the administered dose. 
 
Synthetic carboxylated analogues of 6-Ethy-CA: 
The following analogues have been previously studied: 
INT-777 a C6-Ethyl analogues of CA with a C23-Methyl (S). 
INT-1075 a C6-Ethyl analogues of CA with a C23-Methyl (R). 
The iv and id infusions of INT-777 significantly increased the bile flow rate reaching 
the highest values found in all the studied analogues as reported in table X. The effect is 
also much higher than that obtained after infusion of CA at the same dose. 
The iv infusion of INT-1075 also increased the bile flow rate but this effect was 
significantly lower than that observed for the isomer INT-777. 
INT-777 presented the most potent choleretic effect and this is related to its structure; a 
methyl group in the C-23 position partially prevents conjugation and this molecule can 
undergo a cholehepatic shunt pathway, like that observed for nor-BA and C-23-Methyl 
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analogues of UDCA (previously studied in our laboratory (Clerici et al. 1992; Pellicciari 
et al. 1989, 1985, 1984; Roda et al. 1988a, 1987, 1988; Gioiello et al. 2012).  
None of them is cholestatic at the administered dose. 
 
Synthetic sulphonates and sulphate analogues of 6-Ethyl-CA: 
A series of side sulphate and sulphonate analogues of 6-Ethyl-CA have been previously 
studied such as INT-1244 . 
More recently INT-2021 a C23-Methy sulphate of 6-Ethy-CA and INT-2023 a sulphate 
analogue of 6-Ethyl-CA have studied in this work.  
During infusion experiments INT-1244 presents a choleretic effect, that is more evident 
after id infusion; INT-2021 and INT-2023 induces a slight choleresis only after iv 
administration.  
None of them is cholestatic at the administered dose. 
 
Synthetic carboxylates analogues of CDCA and CA containing a 16β- hydroxyl: 
INT-1212 is a synthetic analogue containing C6-Ethyl and two hydroxyl group in C-3α 
and C-16β position and INT-2024 a similar structure with one more hydroxyl in C-12α 
position. 
The results of binding assays indicate that the BA with C-16β hydroxyl present 10 times 
more activity on FXR than on TGR5. Moreover the 16 hydroxyl group is present in 
many natural occurring BA in fish and reptiles [29]. 
INT-2024 does not modify the bile flow both after id and iv infusions. This 
phenomenon could be due to its high hydrophilicity (LogP(A-) = -0.05) which makes it 
more similar to the conjugated BA, instead of the derivatives of CA. 
None of them is cholestatic at the administered dose. 
 
Taurine and glycine conjugated analogues: 
The following Glycine and Taurine analogue have been studied: 
Tau-INT777, a Taurine conjugate of C6-Ethyl analogues of CA with a C23-Methyl (S) 
Gly-INT777, a Glycine conjugate of C6-Ethyl analogues of CA with a C23-Methyl (S) 
Tau-INT-1212, a Taurine conjugate of C6-Ethyl analogues of CDCA with two hydroxyl 
group in C-3α and C-16β position. 
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The induced bile flow after id and iv administrations of the reference compound 
TCDCA is similar to the control rat being at the administered dose not toxic.  
The infusion of T-INT-777 and G-INT-777 induces a slight choleresis in respect to 
TCDCA and the effect is slightly higher after iv administration. 
The choleresis after iv administrations of Tau-INT-1212 is similar to TCDCA and 
control rats and higher after iv infusion. 
None of them is cholestatic at the administered dose. 
 
4.2.2. BA secretion rates and hepatic metabolism after id and iv 
administration 
   
Synthetic analogues of 6-Ethyl-CDCA: 
In previous research we studied the biliary secretion after iv and id administration of 
CDCA. After iv administration the compound is efficiently secreted in bile, completely 
metabolized to its taurine conjugated form; the same is observed after id administration: 
the maximum secretion rate is slightly lower, but the total recovery calculated by the 
AUC is similar to that after iv administration. 
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Figure 4.2: Mean secretion rates versus time of CDCA in femoral (n = 3) and duodenal (n = 3) 
experiments administered at a dose of 1 µmol/kg/min for 1 hour. Standard deviations are also reported. 
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This compound is fully metabolized since it presents a relatively high lipophilicity and 
the conjugation with taurine renders the molecule much more hydrophilic and therefore 
able to be secreted into bile. 
 
OHHO
OH
O
INT-747 OHHO
OH
O
INT-855
 
 
Similarly to CDCA is has been previously reported that INT-747 is efficiently secreted 
in bile after iv administration, primarily as taurine conjugate. The maximum secretion 
rate is achieved at 120-150 minutes, just at the end of the infusion period (the 60 
minutes-infusion begins after 75 minutes of steady state). The maximum secretion rate 
is 0.96 µmol/kg/min, close to the maximum achievable according to the administered 
dose of 1 µmol/kg/min (an example of the profiles of INT-747 is shown in Figure 4.3 
below). 
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Figure 4.3: Mean secretion rates versus time of INT-747 in femoral (n = 3) and duodenal (n = 3) 
experiments administered at a dose of 1 µmol/kg/min for 1 hour. Standard deviations are also reported. 
 
It had previously reported that the behaviour of INT-747 is similar to that of natural 
dihydroxy BA such as CDCA or UDCA, which are efficiently secreted into bile only as 
	 89
taurine conjugates since they have relatively high lipophilicity with LogP(A-) values 
similar to CDCA or even higher. Differently, trihydroxy BA such as cholic acid can be 
also partially secreted as such in unconjugated form thanks to the relatively lower LogP 
as a result of one more hydroxyl. Moreover the extent of BA secretion in the 
unmodified form is related to its lipophilicity and administered dose, and it is species-
dependent. 
In a previous studies the PK and metabolism has been carefully evaluated and the main 
achieved results are summarized. 
The kinetics of the biliary secretion after iv administration and the extent of albumin 
binding suggest that the hepatic uptake and secretion of INT-747 is quite similar to that 
of natural analogues like CDCA and the rate of hepatic secretion is related to that of 
taurine conjugation mediated by a CoA activation and hepatic taurine availability. As 
previously shown the preferential conjugation with taurine is peculiar for the rat; in 
other animal species (pig, hamster, rabbit) and in man this compound is preferentially 
conjugated with glycine and only to a less extent with taurine . 
According to these data, liver uptake and secretion of INT-747 are efficient and its 
recovery in bile as a taurine conjugated is almost complete. 
The hepatic metabolism of INT-747 produces mainly the taurine conjugated form 
similarly to CDCA having a similar side chain structure The taurine conjugation process 
appears efficient at the administered dose. Traces (less than 0.02%) of glycine conjugate 
are also present, and a small amount of INT-747 (in the order of 0.1-0.3%) is secreted in 
bile in unconjugated form.  
After id infusion INT-747 like CDCA is secreted into bile as taurine conjugate and its 
recovery is almost complete, similarly to that observed after iv infusion. The maximum 
secretion rate is achieved at 180 minutes (i.e., 60 minutes after the end of infusion). The 
maximum secretion rate is 0.80 µmol/kg/min, slightly lower than that measured after iv 
infusion as a results of the dilution effect in the intestine due to the administration by 
duodenal infusion. The taurine conjugation appears efficient at the administered dose. 
Trace amounts (less than 0.2%) of the compound are also conjugated with glycine and a 
similar amount is secreted as such in bile.  
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It has been previously reported that the biliary secretion kinetics of the analogue 
INT855, a lipophilic molecule having a C-23 Methyl was quite different to CDCA and 
INT-747.  
After iv and id administrations, INT-855 is secreted poorly or not secreted as such 
(0.0007 and 0.0003 µmol/kg/min, respectively after iv and id administration) in bile and 
the only metabolite identified so far in bile is a glucuronide derivative (0.01 or 0.009 
µmol/kg/min, respectively after iv and id administration) and to a much less extent as a 
taurine conjugate (0.0025 and 0.0020 µmol/kg/min, respectively after iv and id 
administration).  
 The glucuronide formation is the rate limiting step allowing the partial recovery of the 
compound in bile with presumably high intrahepatic concentration. 
INT855 presents peculiar ADME and PK differences from other CDCA analogues. This 
molecule is highly liphophilic (LogP(A-) = 2.9) and cannot be secreted in bile as such. 
Similarly CDCA and INT-747 were not recovered as such in bile but the efficient side 
chain taurine conjugation allowed to recover these compounds into bile almost 
completely as taurine conjugated in rat. 
The 23-Methyl group almost completely prevents the conjugation pathway and the INT-
855 needs to be conjugated by an alternative pathway in order to be excreted into bile. 
The glucuronide conjugation is the main metabolite recovered in bile. Moreover the 
recovery of this compound is very low suggesting that the compound will be retained by 
the liver and slowly secreted into bile. 
We expected that at higher doses or under sub-chronic administration this compound 
could be slightly toxic to liver cells. 
These basic studies together with previously carried out in Prof. Roda’s Lab allows to 
design new analogues with a suitable pharmacokinetic and metabolism to distribute in 
the target organ as required to act on the molecular target so far identified. 
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Synthetic sulphonate and sulphate analogues of 6-Ethyl-CDCA: 
 
OSO3H
OHHO INT-767
 
 
Other CDCA analogues have been previously designed with the rationale to modify the 
side chain structure replacing the carboxyl group with a sulphate ester or a sulphonate 
group trying to mimic the structure of a taurine conjugate in term of acidic character of 
the molecule, having these derivative a very low pKa similarly to the taurine conjugated 
analogues. 
After iv infusion of INT-767 a fast appearance in bile is observed accounting for a rapid 
hepatic uptake and secretion of the compound as such but the maximum secretion rate is 
lower that CDCA and INT-747. 
In the id experiments the secretion rate is slower as a result of the poor intestinal 
absorption resulting by the relatively low LogP(A-).  
These data show that INT-767 is still absorbed by the intestine, efficiently taken up by 
the liver and promptly secreted into bile partially unmodified and partially metabolized 
to a glucuronide conjugate. 
In the id infusion the glucuronide derivative formation is much less than the iv 
experiments in which the glucuronide is present in a concentration similar to intact INT-
767. In the iv experiment a higher intrahepatic concentration of INT-767 is reached as a 
result of an efficient hepatic uptake of INT-767. The higher intrahepatic concentration 
requires an increased glucuronidation process to facilitate the secretion of the compound 
in bile as a mechanism of toxicity prevention. Under this condition a larger amount of 
INT-767 is present as a glucuronide.  
In conclusion the presence of the sulphate group in the side chain facilitates the biliary 
secretion of the molecule as such, unmodified, in respect to CDCA which is fully 
taurine conjugated. As a consequence, INT-767 could accumulate in the liver cells 
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causing toxicity since its hepatic residence time depends upon the rate of amidation with 
taurine and glycine or the elimination as such or by alternative metabolic pathways. 
 
Synthetic carboxylated analogues of 6-Ethy-CA: 
 
OH
OHHO
OH
O
INT-777
OH
OHHO
OH
O
INT-1075
 
 
As a part of the previous structure-activity relationship program developed in the 
laboratory, analogues of CA all containing the 6-Ethyl were synthesized and admitted to 
the complete physico-chemical and biological screening. 
The first analogue developed in 2008 was INT-777. 
The biliary secretion of INT-777 after iv administration was efficient and the compound 
was recovered in bile unmodified at a relatively high percentage (80-90%) of the 
administered dose. 
The kinetic secretion profile indicates that INT-777 was efficiently taken up by the liver 
and secreted in bile largely unmodified and to a lesser extent (10%) as 23 Methyl 
isomer conjugated with taurine (T-INT-1075). 
The discovery of the INT-777 isomerization was very important in the structure-activity 
relationship studies and the metabolite (INT-1075) was synthesized and admitted to this 
study (Pellicciari et al. 2009).  
After id administration the recovery of INT-777 in bile was lower than after iv 
administration suggesting that the compound is not efficiently absorbed by the intestine.  
Taking into account the physico-chemical properties of INT-777, we expected that this 
compound would be moderately absorbed by a passive diffusion mechanism (LogP(A-) 
= 1.44) and that an active mechanism was not involved.  
When the isomer INT-1075 was administered, the kinetic profile of the compound 
showed that it was metabolized by the liver more extensively than INT-777. The 
compound is secreted in bile as such and as taurine conjugate. With respect to its 
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diastereoisomer INT-777, the percentage of conjugation is higher (30-40%) and the 
maximum secretion rate of the unconjugated form is lower (60-70%).  
The authors of the study suggest that the C-23(R) isomer (INT-1075) presents a side 
chain geometry and Methyl orientation more suitable for the amidation process 
compared to the isomer (S) which is secreted as the unconjugated (INT-777) form at a 
higher percentage (80-90%). The conjugation with taurine contributes to the improved 
INT-1075 recovery in bile which is approximately 70% to 80% of the administered 
dose. Other minor metabolites, including glucuronides, have been identified in bile in 
trace amount but the formation of glucuronides could become relevant if the molecule is 
administered at higher doses. 
From these previous studies the role of side chain structure and hydroxyl substituents 
has been further clarified and it has proved very useful to design the more recent 
molecules studied in the present work. 
The presence of the methyl group in the C-23 position hinders the physiological 
conjugation process with taurine and glycine which is relevant for efficient secretion of 
almost all naturally occurring carboxylated BA. This is crucial for lipophilic dihydroxy-
BA and to a lesser extent for trihydroxy-BA.  
The presence of three hydroxyl groups allows the molecule to be efficiently taken up by 
the liver and secreted into bile. In addition, the 6-Ethyl group prevents the intestinal 
bacteria 7-dehydroxylation as observed previously for 6-Methyl substituted BA [17].  
 
Synthetic sulphonates and sulphate analogues of 6Ethyl-CA: 
 
OHHO
OH SO3H
INT-1244 OHHO
OH
OSO3H
INT-2023 OHHO
OH
OSO3H
INT-2021
 
The biliary secretion of INT-1244, has been previously studied. More recently INT-
2023 and INT-2021 have been studied.  
INT-2023 and INT-2021 after iv administration were efficient taken –up by the liver 
and almost completely secreted and recovered in bile as shown for INT-2023 and INT-
2021 Figure 4.4 and 4.5 below). 
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Figure 4.4:Mean secretion rates versus time of INT-2023 in femoral (n = 3) and duodenal (n = 3) 
experiments administered at a dose of 1 µmol/kg/min for 1 hour. Standard deviations are also reported. 
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Figure 4.5: Mean secretion rates versus time of INT-2021 in femoral (n = 3) and duodenal (n = 3) 
experiments administered at a dose of 1 µmol/kg/min for 1 hour. Standard deviations are also reported. 
 
The kinetic profiles indicate that the analogues were efficiently taken up by the liver 
and secreted in bile as such without hepatic metabolism. On the contrary, after id 
administration (orally) the recovery in bile was much lower suggesting that the 
compounds are poorly absorbed by the intestine. 
The compounds are secreted in bile unmodified both after iv and id administration. 
According to the physico-chemical properties, we expected that these compounds would 
be poorly absorbed by the intestine through a passive diffusion mechanism. Their low 
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partition coefficient in octanol/water LogP(A-) (0.7 for INT-1244 and INT-2021 and 0.6 
for INT-2023) accounts for these results, since these values should be higher than 1 for 
reasonable passive diffusion possibility. Moreover, an active mechanism mediated by 
intestinal transporters like that occurring for the hydrophilic taurine conjugated BA did 
not seem to be involved.  
 
Synthetic carboxylates analogues of containing a 16β-hydroxyl: 
 
OHHO
OH
O
OH
INT-1212
OH
OHHO
OH
O
OH
INT-2024
 
 
It has been reported that INT-1212, after iv infusion, was extensively metabolized by 
the liver to form the taurine conjugate and was secreted into bile partially in this form 
and also unmodified. The conjugation with taurine improved its recovery in bile which 
is approximately 70% of the administered dose. The INT-1212 molecule behaved 
similarly to CA, as it can be secreted as such (CDCA can be secreted into bile only 
conjugated with taurine) and, despite the methyl group in the C-23 position, INT-1212 
can be partially amidated. 
The INT-1212 biliary secretion after id administration was lower than after the iv 
experiments, suggesting that the intestinal absorption of the molecule is not efficient 
like other BA. This molecule undergoes hepatic metabolism like naturally occurring BA 
with similar physico-chemical properties such as lipophilicity (LogP(A-) = 1.6). 
After both iv and id administration experiments the main metabolite found was INT-
1212 conjugated with taurine but in different percentages in fact after iv administration 
INT-1212 is present in bile 70% as tauro and 30% as free bile acid while after id 
administration we find it 70% and 30% respectively as free and tauro-conjugated form. 
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The biliary secretion of INT-2024 (an example of the profiles of INT-2024 is shown in 
Figure 4.6 below) after iv administration was efficient and the compound was recovered 
in bile at a relatively high percentage (80-90%) of the administered dose.  
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Figure 4.6: Mean secretion rates versus time of INT-2024 in femoral (n = 3) and duodenal (n = 3) 
experiments administered at a dose of 1 µmol/kg/min for 1 hour. Standard deviations are also reported. 
 
The kinetic profile indicates that INT-2024 was efficiently taken up by the liver and 
secreted in bile mainly unmodified and also, to a lesser extent (10%) conjugated with 
taurine (data are reported in section 2.2.4.). No other metabolites have been identified in 
bile maybe because of the high hydrophilicity of this compound compared with INT-
1212. 
After id administration the recovery in bile for INT-2024 was lower than the recovery 
after iv administration suggesting that the compound is not efficiently absorbed by the 
intestine. We expected that INT-2024 would be absorbed by active mechanism 
(LogP(A-) = -0.05) which is a derivative of CA but with an additional hydroxyl group 
in 16β which breaks the lipophilicity of BA β face. 
 
Taurine and glycine conjugated analogues: 
 
OHHO
OH
O
NH
SO3H
T-INT-777 OHHO
OH
O
NH
OH
O
G-INT-777 OHHO
O
NH
OH
SO3H
T-INT-1212
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When the natural BA (T-CDCA) and related analogues (T-INT-777, G-INT-777 and T-
INT-1212) were iv administered as taurine or glycine conjugates, the recovery in bile 
was almost complete and similar to that of trihydroxy BA and no additional metabolites 
have been foud.(Profiles of T-INT-777 and G-INT-777 are shown in Figure 4.7 and 4.8 
below). 
 
IV ID ADMINISTRATIONS
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0 30 60 90 120 150 180 210 240 270
Time (min)
Se
cr
et
io
n 
(u
m
ol
/m
in
/K
g)
T-INT777 IV
T-INT777 ID
Infusions 
 
Figure 4.7: Mean secretion rates versus time of T-INT-777 in femoral (n = 3) and duodenal (n = 3) 
experiments administered at a dose of 1 µmol/kg/min for 1 hour. Standard deviations are also reported. 
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Figure 4.8: Mean secretion rates versus time of G-INT-777 in femoral (n = 3) and duodenal (n = 3) 
experiments administered at a dose of 1 µmol/kg/min for 1 hour. Standard deviations are also reported. 
 
T-CDCA, T-INT-777, G-INT-777 and T-INT-1212 are secreted into bile unmodified 
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both after iv and id administration..  
The relatively low recovery after id infusions, for T-CDCA, T-INT-777 and T-INT-
1212, is due to the mode of absorption : only in the ileum by an active mechanism 
peculiar to the taurine/glycine conjugated BA. 
The good recovery after id infusion for G-INT-777 is due to the mode of absorption. 
The glycine conjugates have a rather efficient active absorption in the ileum but they are 
liable also of passive diffusion in all the intestine. 
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Table 4.3. summarize the main metabolites so far identified for the studied BA. 
Hepatic metabolism in rat Administered 
BA I.V. I.D. 
Natural BA 
CDCA T-CDCA(95%)>> CDCA(5%) T-CDCA(95%)>> CDCA(5%) 
Synthetic analogues of 6-Ethyl-CDCA 
INT-747* T-INT-747(99.7%) >> INT-747(0.3%) 
T-INT-747(99.7%) >> INT-
747(0.3%) 
INT-855* 
GLUC-INT-855(75%) >> T-INT-
855(18%) > INT-855(7%) 
GLUC-INT-855(75%) >> T-INT-
855(18%) > INT-855(7%) 
Synthetic sulphonate and sulphate analogue of 6-Ethyl-CDCA 
INT-767* 
INT-767(60%) > GLUC-INT-
767(40%) 
INT-767(75%) >GLUC-INT-
767(25%) 
Synthetic carboxylated analogues of 6-Ethy-CA 
INT-777* INT-777(90%) >> T-INT-1075(10%) INT-777(70%) > T-INT-1075 (30%) 
INT-1075* INT-1075(70%) > T-INT-1075(30%) - 
Synthetic sulphonates and sulphate analogues of 6Ethyl-CA 
INT-1244* NONE NONE 
INT-2021 NONE NONE 
INT-2023 NONE NONE 
Synthetic carboxylates analogues of containing a 16β- hydroxyl 
INT-1212* T-INT-1212(70%) >> INT-1212(30%) T-INT-1212(30%) < INT-1212(70%) 
INT-2024 INT-2024(90%) >> T-INT-2024(10%) INT-2024(50%)=T-INT-2024 (50%) 
Taurine and glycine conjugated analogues 
T-INT-777 NONE NONE 
T-INT-1212 NONE NONE 
G-INT-777 NONE NONE 
T-CDCA NONE NONE 
 (*)Data obtained in previous works 
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4.3. Conclusions 
 
Bile secretion increases during infusion of all BA studied as a result of BA-dependent 
flow. The modulation of bile flow depends on the amount of BA secreted into bile and 
on the qualitative composition of bile induced by their secretionand metabolism.  
Synthetic sulphonates and sulphate analogues of CA (INT-2023, INT-2021 and INT-
1244) and CDCA (INT-767) showed a moderate or absent choleretic effect. Only INT-
2021 shows a choleretic effect maybe due to the presence of the methyl group at C23, 
that, preventing the amidation, facilitates the ductular absorption and recycling via the 
chole-hepatic shunt pathway pumping bicarbonate and water into bile. 
This phenomenon is shared by all the carboxylated BA with a C-23 Methyl group such 
as INT-2021, INT-777 and INT-1075. 
When administered as taurine or glycine conjugates, they show a weaker choleretic 
effect; this is particularly evident for dihydroxy BA (T-CDCA and T-INT-1212) and, to 
a lesser extent, for trihydroxy BA (T-INT-777 and G-INT-777). Their hydrophilicity is 
much higher than that of the respective unconjugated BA due to the polar characteristics 
of the amide bond and the sulphonic acid terminal group (fully ionized and more 
hydrated) which is not balanced by the increased length of the side chain. As a result, 
they do not follow a cholehepatic shunt pathway and their retention in the liver cell is 
shorter than the corresponding unconjugates showing a very fast hepatic transit time.  
Considering these findings, the induced bile flow of unconjugated BA seems highly 
related to the amount of unconjugated forms reabsorbed via a cholehepatic shunt. This 
is reasonable for the dihydroxy BA which can diffuse passively and for the 23-Methyl 
analogues.  
 
The structural modification profoundly modify the pharmacokinetics and metabolism in 
respect to the natural analogues CDCA and CA. We can summarize some important 
features observed in these studies for these bile acid analogs: 
 
 Higher stability toward bacteria metabolism since the bacterial 7-
dehydroxylation process is almost absent due to the steric hindrance of the ethyl 
group in six position.  
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 The presence of the methyl group in the C-23 (S) position of INT-777 partially 
prevents conjugation with taurine in respect to his isomer INT-1075; due to its 
low lipophilicity however the molecule can be efficiently secreted unmodified.  
 Unconjugated trihydroxy BA analogues are more hydrophilic than dihydroxy 
BA analogues and this accounts for their lower recovery in bile after id 
administration due to lower intestinal absorption as documented by the lower 
LogP values. 
 For lipophilic dihydroxy BA analogues the hepatic conjugation step appears 
essential for biliary secretion. Carboxylated BA with a conventional side chain 
length and structure are amidated with taurine and glycine and secreted in bile. 
Modification in the side chain length and the introduction of a 23-Methyl group 
prevent conjugation with a retention of the molecule in the liver and activation 
of alternative conjugation pathways to allow their secretion into bile and 
preventing their potential hepatic toxicity. 
 Taurine/Glycine conjugated analogues are secreted in bile as such with a fast 
kinetic profile . These analogues are not metabolized either in the live or in the 
intestine. Glycine conjugates analogues could be absorbed via active and passive 
(if relatively lipophilic) mechanisms while taurine conjugated bile acid 
analogues only by active mechanism in the ileum. The use of these analogues 
could be limited by the potential poor intestinal absorption also possibly due to a 
competition in the transport with the natural BA. 
 The presence of the sulphonate group in the side chain facilitates the biliary 
secretion in respect to the same synthetic carboxylated analogues. The synthetic 
sulphonated analogues can be secreted as such and additionally as glucuronide 
derivates. Moreover their intestinal absorption by passive diffusion is limited by 
the relatively high hydrophilicity. 
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